[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5218
1. Mathews MS, Duma CM, Brant-Zawadzki M, Hasso A, Westhout FD, Klein DJ, Vanhorn D: Extramedullary hematopoeisis within a convexity meningioma. Surg Neurol; 2008 May;69(5):522-5; discussion 525
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hematopoiesis outside the bone marrow is known to occur in patients with severe anemia, leukemia, polycythemia, or myelofibrosis, and in patients affected by chronic poisoning by marrow-toxic substances.
  • A hematoxylin-eosin-stained biopsy specimen showed whorls of tumor cells, diagnostic of a meningioma.
  • Flow cytometric evaluation confirmed the clinical suspicion of an underlying chronic lymphocytic leukemia.

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714768.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR: The BCL-2 family reunion. Mol Cell; 2010 Feb 12;37(3):299-310
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • B cell CLL/lymphoma-2 (BCL-2) and its relatives comprise the BCL-2 family of proteins, which were originally characterized with respect to their roles in controlling outer mitochondrial membrane integrity and apoptosis.
  • Here we will discuss the mechanisms and functions of the BCL-2 family in the context of these pathways, highlighting the complex integration and regulation of the BCL-2 family in cell fate decisions.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2009 Nov 13;36(3):355-63 [19917245.001]
  • [Cites] Mol Cell. 2009 Nov 13;36(3):487-99 [19917256.001]
  • [Cites] Mol Cell. 2009 Nov 25;36(4):696-703 [19941828.001]
  • [Cites] Nature. 2010 Jan 7;463(7277):103-7 [20023629.001]
  • [Cites] J Biol Chem. 2008 Apr 18;283(16):10892-903 [18281291.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):13123-32 [17337444.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):405-13 [17377525.001]
  • [Cites] Apoptosis. 2007 May;12(5):897-911 [17453159.001]
  • [Cites] J Cell Biol. 2007 Apr 23;177(2):277-87 [17452531.001]
  • [Cites] EMBO J. 2007 May 16;26(10):2527-39 [17446862.001]
  • [Cites] Cell Death Differ. 2007 Jun;14(6):1086-94 [17332775.001]
  • [Cites] Autophagy. 2007 Jul-Aug;3(4):374-6 [17438366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11649-54 [17606912.001]
  • [Cites] Genes Dev. 2007 Aug 1;21(15):1937-48 [17671092.001]
  • [Cites] Nat Cell Biol. 2007 Sep;9(9):1057-65 [17721514.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):561-8 [17643073.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19500-5 [18048346.001]
  • [Cites] Cell. 2008 Jan 11;132(1):27-42 [18191218.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16202-12 [10821866.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):2060-71 [10950869.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6453-62 [11102440.001]
  • [Cites] Dev Cell. 2001 Oct;1(4):515-25 [11703942.001]
  • [Cites] Dev Cell. 2002 Jan;2(1):55-67 [11782314.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):19-30 [12086884.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):183-92 [12242151.001]
  • [Cites] Cell. 2002 Nov 1;111(3):331-42 [12419244.001]
  • [Cites] J Cell Biol. 2002 Dec 23;159(6):931-8 [12499352.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):577-90 [12667443.001]
  • [Cites] Science. 2003 Apr 4;300(5616):135-9 [12624178.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36373-9 [12783892.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94 [14996493.001]
  • [Cites] Nat Cell Biol. 2004 May;6(5):443-50 [15077116.001]
  • [Cites] Mol Biol Cell. 2004 Nov;15(11):5001-11 [15356267.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] Cell. 1989 Apr 7;57(1):79-88 [2649247.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):331-3 [2250704.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13829-34 [9153240.001]
  • [Cites] J Virol. 1998 Nov;72(11):8586-96 [9765397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):105-10 [15613488.001]
  • [Cites] Mol Cell. 2005 Feb 4;17(3):393-403 [15694340.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1101-4 [15718471.001]
  • [Cites] Mol Cell. 2005 Feb 18;17(4):525-35 [15721256.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Science. 2005 Sep 9;309(5741):1732-5 [16151013.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35742-50 [16115883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17975-80 [16330765.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):97-108 [16493416.001]
  • [Cites] Mol Cell. 2006 Mar 17;21(6):761-73 [16543146.001]
  • [Cites] Science. 2006 Apr 28;312(5773):572-6 [16645094.001]
  • [Cites] Cancer Cell. 2006 May;9(5):351-65 [16697956.001]
  • [Cites] Cell. 2006 Jul 14;126(1):163-75 [16839884.001]
  • [Cites] Cell. 2006 Jul 14;126(1):177-89 [16839885.001]
  • [Cites] J Cell Biol. 2006 Sep 25;174(7):915-21 [16982799.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(20):7397-408 [17015472.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4738-45 [16966688.001]
  • [Cites] Nature. 2006 Oct 12;443(7112):658-62 [17035996.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):389-99 [17097561.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1348-58 [17115033.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):112-21 [17200714.001]
  • [Cites] Science. 2007 Feb 9;315(5813):856-9 [17289999.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):121-32 [18202696.001]
  • [Cites] Dev Cell. 2008 Feb;14(2):193-204 [18267088.001]
  • [Cites] Nat Immunol. 2008 Apr;9(4):405-14 [18327259.001]
  • [Cites] Trends Cell Biol. 2008 Apr;18(4):157-64 [18314333.001]
  • [Cites] Mol Cell. 2008 May 9;30(3):369-80 [18471982.001]
  • [Cites] J Exp Med. 2008 May 12;205(5):1029-36 [18443228.001]
  • [Cites] Mol Biol Cell. 2008 Jun;19(6):2402-12 [18353969.001]
  • [Cites] Mol Cell. 2008 Jun 20;30(6):678-88 [18570871.001]
  • [Cites] Nature. 2008 Jul 10;454(7201):232-5 [18454133.001]
  • [Cites] J Biol Chem. 2008 Jul 25;283(30):21294-304 [18524770.001]
  • [Cites] Mol Cell. 2008 Aug 22;31(4):557-69 [18691924.001]
  • [Cites] Mol Cell. 2008 Aug 22;31(4):570-85 [18722181.001]
  • [Cites] Cell Death Differ. 2008 Oct;15(10):1564-71 [18551131.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1076-81 [18948948.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):605-10 [19052620.001]
  • [Cites] Cell. 2008 Dec 12;135(6):1074-84 [19062087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20327-32 [19074266.001]
  • [Cites] Mol Cell. 2009 Jan 16;33(1):15-29 [19150424.001]
  • [Cites] J Biol Chem. 2009 Jan 30;284(5):2719-28 [19029119.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1126-32 [19228717.001]
  • [Cites] Nature. 2009 May 21;459(7245):428-32 [19363473.001]
  • [Cites] Autophagy. 2009 Jul;5(5):720-2 [19395874.001]
  • [Cites] Cell Death Differ. 2009 Aug;16(8):1135-45 [19300452.001]
  • [Cites] Science. 2009 Jul 24;325(5939):477-81 [19556461.001]
  • [Cites] Apoptosis. 2009 Aug;14(8):929-34 [19629695.001]
  • [Cites] Nat Cell Biol. 2009 Aug;11(8):958-66 [19578372.001]
  • [Cites] J Cell Biol. 2009 Aug 10;186(3):355-62 [19651893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14397-402 [19706527.001]
  • (PMID = 20159550.001).
  • [ISSN] 1097-4164
  • [Journal-full-title] Molecular cell
  • [ISO-abbreviation] Mol. Cell
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / F32 CA101444; United States / NIAID NIH HHS / AI / R01 AI040646; United States / NIAID NIH HHS / AI / R01 AI040646-16
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  • [Number-of-references] 89
  • [Other-IDs] NLM/ NIHMS337530; NLM/ PMC3222298
  •  go-up   go-down


3. Hogan M, Claffey J, Pampillón C, Tacke M: Synthesis and cytotoxicity studies of new morpholino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs. Med Chem; 2008 Mar;4(2):91-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When these titanocenes were tested against LLC-PK cells, the IC(50) values obtained were of 24, 36, and 41 microM respectively.
  • The most cytotoxic titanocene in this paper (5a) with an IC(50) value of 24 microM is found to be almost ten times less cytotoxic than cis-platin, which showed an IC(50) value of 3.3 microM when tested on the epithelial pig kidney LLC-PK cell line, and approximately 2 times less cytotoxic than its dimethylamino-functionalised analogue.
  • [MeSH-minor] Animals. Cyclopentanes. Inhibitory Concentration 50. LLC-PK1 Cells. Structure-Activity Relationship. Swine

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336326.001).
  • [ISSN] 1573-4064
  • [Journal-full-title] Medicinal chemistry (Shāriqah (United Arab Emirates))
  • [ISO-abbreviation] Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclopentanes; 0 / Morpholines; 0 / Organometallic Compounds; 1271-29-0 / titanocene; 19W699IKIE / fulvene
  •  go-up   go-down


Advertisement
4. Richmond J, Bryant R, Trotman W, Beatty B, Lunde J: FISH detection of t(14;18) in follicular lymphoma on Papanicolaou-stained archival cytology slides. Cancer; 2006 Jun 25;108(3):198-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FISH detection of t(14;18) in follicular lymphoma on Papanicolaou-stained archival cytology slides.
  • BACKGROUND: The t(14;18)(q32;q21) translocation is present in about 85% of follicular lymphomas (FL) and can be identified using fluorescence in situ hybridization (FISH).
  • METHODS: Cases included 35 FL, 6 small lymphocytic lymphomas/chronic lymphocytic leukemias (SLL/CLL), 4 mantle cell lymphomas (MCL), 4 marginal zone lymphomas (MZL), 1 lymphoplasmacytic lymphoma (LPL), and 10 reactive lymphoid tissues (RLT).
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Lymphoma, Follicular / pathology. Translocation, Genetic
  • [MeSH-minor] Biopsy, Fine-Needle. Humans. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoid Tissue / pathology. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / pathology. Staining and Labeling

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671111.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. da Silva R, Saraiva J, de Albuquerque S, Curti C, Donate PM, Bianco TN, Bastos JK, Silva ML: Trypanocidal structure-activity relationship for cis- and trans-methylpluviatolide. Phytochemistry; 2008 Jun;69(9):1890-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of the compounds was assessed by the MTT method using LLC-MK2 cells.
  • Trans-methylpluviatolide displayed low toxicity for LLC-MK2 cells, with an IC50 of 6.53 mM.
  • [MeSH-minor] Animals. Cell Line. Macrophages / drug effects. Macrophages / metabolism. Mice. Molecular Structure. Nitric Oxide / biosynthesis. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479721.001).
  • [ISSN] 0031-9422
  • [Journal-full-title] Phytochemistry
  • [ISO-abbreviation] Phytochemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lactones; 0 / Lignans; 0 / Trypanocidal Agents; 0 / methylpluviatolide; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


6. Cutrona G, Colombo M, Matis S, Reverberi D, Dono M, Tarantino V, Chiorazzi N, Ferrarini M: B lymphocytes in humans express ZAP-70 when activated in vivo. Eur J Immunol; 2006 Mar;36(3):558-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B lymphocytes in humans express ZAP-70 when activated in vivo.
  • Recently, this important signaling element was detected in leukemic B cells from a subgroup of patients with B cell chronic lymphocytic leukemia (B-CLL).
  • The cDNA sequence of B cell ZAP-70 was the same as that in T cells.
  • Germinal center B cells and plasma cells had a substantial proportion of ZAP-70+ cells, while memory and follicular mantle B cells, which contain low numbers of activated B cells, expressed relatively little ZAP-70.
  • A cell fraction of IgD+, CD38+ B cells, which are comprised of many in vivo activated B cells, exhibited the highest levels of ZAP-70.
  • In these B cells, the expression of ZAP-70 correlated with that of CD38 and not with that of CD5, a hallmark of B-CLL cells.
  • B-CLL cells are activated cells and their ZAP-70 expression reflects a normal property of activated B cells populations rather than a neoplastic aberration.
  • [MeSH-major] B-Lymphocytes / immunology. Gene Expression Regulation, Enzymologic / immunology. Lymphocyte Activation / immunology. ZAP-70 Protein-Tyrosine Kinase / immunology
  • [MeSH-minor] Antigens, CD38 / immunology. Antigens, CD5 / immunology. Cells, Cultured. Germinal Center / cytology. Germinal Center / immunology. Humans. Immunoglobulin D / immunology. Killer Cells, Natural / cytology. Killer Cells, Natural / enzymology. Killer Cells, Natural / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Membrane Glycoproteins / immunology. Palatine Tonsil / cytology. Palatine Tonsil / immunology. T-Lymphocytes / cytology. T-Lymphocytes / enzymology. T-Lymphocytes / immunology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482508.001).
  • [ISSN] 0014-2980
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR018535; United States / NCI NIH HHS / CA / R01 CA 81554; United States / NCI NIH HHS / CA / R01 CA 87956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Immunoglobulin D; 0 / Membrane Glycoproteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


7. Allgeier T, Garhammer S, Nössner E, Wahl U, Kronenberger K, Dreyling M, Hallek M, Mocikat R: Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia. Cancer Lett; 2007 Jan 8;245(1-2):275-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia.
  • Hybrids generated from tumor cells and dendritic cells (DC) have been proposed as tools for treating malignant disease.
  • Here, we study the underlying principles and the feasibility for the adjuvant therapy of human B cell chronic-lymphocytic leukemia (B-CLL).
  • CLL cells and allogeneic DC were only mixed or additionally fused.
  • Using a combination of FACS and fluorescence microscopic analyses, we show that DC-CLL hybrids can be successfully generated.
  • We made a systematic comparison of the immunostimulatory capacities of different stimulator cell populations, including DC-CLL fusion samples, unfused mixtures of DC and CLL cells as well as DC or tumor cells alone.
  • This could be explained by the capture of antigens from surrounding leukemia cells by DC during co-cultivation.
  • Although fusion frequencies were low, PBMC stimulation was significantly more effective when the mixtures were subjected to cell fusion.
  • The most potent stimulus was provided by DC-CLL fusion samples derived from mature DC, probably due to their enhanced costimulatory capacity.
  • In summary, DC-tumor cell hybrids might be feasible in the treatment of B-CLL.
  • It should be considered that FACS analysis is not sufficient to assess fusion frequencies and that interactions between unfused DC and CLL cells also result in PBMC activation.
  • [MeSH-major] Dendritic Cells / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516377.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD11c; 0 / Antigens, CD19; 0 / Antigens, CD3; 0 / Antigens, CD5; 0 / Antigens, CD80; 0 / Antigens, CD86; 0 / CD83 antigen; 0 / HLA-DR Antigens; 0 / Immunoglobulins; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


8. Delgado J, Pillai S, Phillips N, Brunet S, Pratt G, Briones J, Lovell R, Martino R, Ewing J, Sureda A, Milligan DW, Sierra J: Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis. Ann Oncol; 2009 Dec;20(12):2007-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis.
  • BACKGROUND: Reduced-intensity conditioning (RIC) allogeneic haemopoietic cell transplantation (allo-HCT) is increasingly considered as a therapeutic option for younger patients with poor-risk chronic lymphocytic leukaemia (CLL).
  • In this retrospective analysis, we assessed the outcomes of CLL patients undergoing RIC allo-HCT compared with a group of matched controls that were candidates for transplantation but did not have a suitable donor or refused the procedure.
  • Haemopoietic cell grafts were harvested from HLA-matched siblings (27) and unrelated donors (7).
  • Matching variables were age at diagnosis and time to first CLL-specific therapy.
  • RESULTS: Both patient groups were well balanced in terms of cytogenetics by FISH, CD38 and ZAP-70 expression, and immunoglobulin heavy-chain variable region mutational status.
  • Median overall survival was 113 months for HCT patients and 85 months for controls when calculated from time of diagnosis (P = 0.072) and 103 and 67 months, respectively, when calculated from time of first therapy (P = 0.041).
  • CONCLUSION: RIC allo-HCT is a reasonable option for patients with high-risk CLL.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596701.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Zenz T, Benner A, Döhner H, Stilgenbauer S: Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle; 2008 Dec 15;7(24):3810-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.
  • The importance of studying p53 pathway defects in CLL has been fostered by the demonstration of the fundamentally different clinical course of patients with 17p deletion, where the clinical course is, contrary to most patients with CLL, very poor.
  • The demonstration of the resistance to chemotherapy and mutation of the remaining TP53 allele explains the clinical presentation of CLL with 17p deletion.
  • Here we review recent evidence that TP53 mutation in the absence of the deletion of 17p shows a similar clinical and biological course in CLL.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Cell Cycle Proteins / genetics. Chromosomes, Human, Pair 17. DNA Damage. DNA-Binding Proteins / genetics. Drug Resistance, Neoplasm. Gene Deletion. Humans. MicroRNAs / genetics. Protein-Serine-Threonine Kinases / genetics. Survival Analysis. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098429.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / MicroRNAs; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Number-of-references] 37
  •  go-up   go-down


10. Liu L, Yang C, Herzog C, Seth R, Kaushal GP: Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochem Pharmacol; 2010 Jan 15;79(2):137-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate the effect of proteasome inhibitors in mitochondrial release of apoptosis-inducing factor (AIF) in cisplatin-exposed renal tubular epithelial cells (LLC-PK(1) cells) and in a model of cisplatin nephrotoxicity.
  • Downregulation of Mcl-1 by small interfering RNA promoted Bax activation and cytochrome c and AIF release, suggesting that cisplatin-induced Mcl-1 depletion and associated Bax activation are involved in the release of AIF.
  • [MeSH-minor] Animals. Blotting, Western. Immunoprecipitation. LLC-PK1 Cells. Male. Mice. Mice, Inbred C57BL. Swine

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19699182.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Novaretti MC, Domingues AE, Manhani R, Pinto EM, Dorlhiac-Llacer PE, Chamone DA: ABO genotyping in leukemia patients reveals new ABO variant alleles. Genet Mol Res; 2008;7(1):87-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABO genotyping in leukemia patients reveals new ABO variant alleles.
  • The aim of the present study was to perform ABO genotyping in patients with leukemia.
  • Blood samples were collected from 108 Brazilian patients with chronic myeloid leukemia (N = 69), chronic lymphoid leukemia (N = 13), acute myeloid leukemia (N = 15), and acute lymphoid leukemia (N = 11).
  • We identified 22 new ABO*variants in the coding region of the ABO gene in 25 individuals with leukemia (23.2%).
  • The majority of ABO variants was detected in O alleles (15/60.0%).
  • Elucidation of the diversity of this gene in leukemia and in other diseases is important for the determination of the effect of changes in an amino acid residue on the specificity and activity of ABO glycosyltransferases and their function.
  • In conclusion, this is the first report of a large number of patients with leukemia genotyped for ABO.
  • The findings of this study indicate that there is a high level of recombinant activity in the ABO gene in leukemia patients, revealing new ABO variants.
  • [MeSH-major] ABO Blood-Group System / genetics. Alleles. Genetic Variation. Leukemia / blood

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273824.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 9007-49-2 / DNA
  •  go-up   go-down


12. Gintowt AA, Germer JJ, Mitchell PS, Yao JD: Evaluation of the MagNA Pure LC used with the TRUGENE HBV Genotyping Kit. J Clin Virol; 2005 Oct;34(2):155-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The current manual sample processing method recommended for use with the TRUGENE HBV Genotyping Kit (TRUGENE HBV; Bayer HealthCare LLC, Tarrytown, NY) is labor-intensive and may be prone to specimen cross-contamination.
  • Performance of TRUGENE HBV used in conjunction with MP sample processing was evaluated further using 22 clinical serum specimens containing low titers of HBV DNA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023890.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


13. Rhyu DY, Kang KS, Sekiya M, Tanaka T, Park JC, Yokozawa T: Active compounds isolated from traditional Chinese prescription Wen-Pi-Tang protecting against peroxynitrite-induced LLC-PK(1) cell damage. Am J Chin Med; 2008;36(4):761-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active compounds isolated from traditional Chinese prescription Wen-Pi-Tang protecting against peroxynitrite-induced LLC-PK(1) cell damage.
  • Wen-Pi-Tang, a traditional Chinese prescription, has been widely used for the treatment of patients with moderate chronic renal failure in China.
  • Although the protective effect of Wen-Pi-Tang on peroxynitrite (ONOO(-))-induced renal tubular epithelial LLC-PK(1) cell damage was elucidated in our previous research, the active components of Wen-Pi-Tang have not yet been fully clarified.
  • Therefore, the major bioactivity of Wen-Pi-Tang against ONOO(-)-induced cytotoxicity in LLC-PK(1) cells was thought to be mediated by (+)-catechin.
  • Although we cannot disregard the synergetic effect of various components in Wen-Pi-Tang, (+)-catechin is a major active compound protecting against ONOO(-)-induced LLC-PK(1) cell damage and may be used as an index to qualify the ONOO(-)-inhibitory activity of Wen-Pi-Tang extract.
  • [MeSH-minor] Animals. Cell Line. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Free Radicals / metabolism. Molsidomine / analogs & derivatives. Molsidomine / pharmacology. Nitric Oxide Donors / pharmacology. Swine

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711772.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Free Radicals; 0 / Nitric Oxide Donors; 0 / wen-pi-tang; 14691-52-2 / Peroxynitrous Acid; 5O5U71P6VQ / linsidomine; 8R1V1STN48 / Catechin; D46583G77X / Molsidomine
  •  go-up   go-down


14. Iglesias-Serret D, Piqué M, Barragán M, Cosialls AM, Santidrián AF, González-Gironès DM, Coll-Mulet L, de Frias M, Pons G, Gil J: Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis; 2010 Feb;15(2):219-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance.
  • Aspirin and other non-steroidal anti-inflammatory drugs induce apoptosis in most cell types.
  • In this study we examined the mechanism of aspirin-induced apoptosis in human leukemia cells.
  • Our results show that aspirin induced apoptosis in leukemia Jurkat T cells independently of NF-kappaB.
  • This alteration of the Mcl-1/Noxa balance was also found in other leukemia cell lines and primary chronic lymphocytic leukemia cells (CLL).
  • Furthermore, in CLL cells aspirin induced an increase in the protein levels of Noxa.
  • [MeSH-major] Apoptosis / drug effects. Aspirin / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Mitogen-Activated Protein Kinases / metabolism. NF-kappa B / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Apoptosis Regulatory Proteins / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Cycloheximide / pharmacology. Cytochromes c / secretion. Drug Screening Assays, Antitumor. Enzyme Activation / drug effects. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. MAP Kinase Kinase Kinases / metabolism. Mitochondria / drug effects. Mitochondria / secretion. Myeloid Cell Leukemia Sequence 1 Protein. Proto-Oncogene Proteins / metabolism

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936928.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BBC3 protein, human; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / NF-kappa B; 0 / PMAIP1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 9007-43-6 / Cytochromes c; 98600C0908 / Cycloheximide; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / MAP3K8 protein, human; R16CO5Y76E / Aspirin
  •  go-up   go-down


15. Mailloux AW, Clark AM, Young MR: NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells. Int J Cancer; 2010 Dec 1;127(11):2598-611
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies demonstrated that NK-dependant increases in CCL22 secretion selectively recruit Tregs toward murine lungs bearing Lewis Lung Carcinoma (LLC).
  • To extend the in vitro studies, the present studies utilized in vivo depletion of NK cells to ascertain the contribution of NK-derived CCL22 toward total CCL22 and subsequent Treg levels in both normal and LLC-bearing lungs.
  • However, NK depletion had the unexpected effect of increasing both CCL22 secretion and Treg levels in the lungs of NK-depleted LLC-bearing mice.
  • Flow cytometry and a series of both immunomagnetic and FACS isolations were used to identify the CCL22-producing cellular fractions in LLC-bearing lungs.
  • A novel CD11b(+)CD11c(+) cell population was identified that accumulates in large numbers in NK-depleted LLC-bearing lung tissue.
  • These CD11b(+)CD11c(+) cells secreted large amounts of CCL22 that may overcompensate for the loss of NK-derived CCL22 in the lungs of NK-depleted LLC-bearing mice.
  • Taken together, these data suggest that NK cells play both a positive and negative role in the regulation of CCL22 secretion and, in turn, the recruitment of Tregs toward LLC-bearing lungs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2000 Feb 21;191(4):661-8 [10684858.001]
  • [Cites] J Immunol. 2009 Mar 1;182(5):2753-65 [19234170.001]
  • [Cites] Int Immunol. 2001 Apr;13(4):459-63 [11282985.001]
  • [Cites] J Leukoc Biol. 2001 Apr;69(4):531-7 [11310838.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):847-53 [11560999.001]
  • [Cites] Science. 2001 Oct 19;294(5542):605-9 [11567106.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2342-8 [12805336.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] Semin Immunol. 2004 Apr;16(2):89-98 [15036232.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Reticuloendothel Soc. 1979 Jun;25(6):623-33 [385867.001]
  • [Cites] Boll Ist Sieroter Milan. 1985;64(1):25-34 [3859302.001]
  • [Cites] J Natl Cancer Inst. 1986 Apr;76(4):745-50 [3457207.001]
  • [Cites] J Natl Cancer Inst. 1986 Dec;77(6):1255-60 [3491925.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1151-64 [7636184.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):275-82 [9568645.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):5027-38 [9794440.001]
  • [Cites] Diabetes. 2005 Feb;54(2):434-42 [15677501.001]
  • [Cites] J Immunol. 2009 Dec 15;183(12):8044-53 [19933856.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5211-20 [15958566.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6169-76 [16237114.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5716-22 [16740709.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):123-31 [17522861.001]
  • [Cites] Blood. 2008 Jan 15;111(2):761-6 [17967942.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2286-93 [18224687.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1733-41 [11238115.001]
  • (PMID = 20198623.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA8566; United States / NIDCR NIH HHS / DE / R01 DE018168-02; United States / NCI NIH HHS / CA / 1R01CA128837; United States / NCI NIH HHS / CA / R01 CA085266-06; United States / NCI NIH HHS / CA / R01 CA085266; United States / NIDCR NIH HHS / DE / R01DE018168; United States / NIDCR NIH HHS / DE / R01 DE018168; United States / NCI NIH HHS / CA / CA128837-01A2; United States / NCI NIH HHS / CA / R01 CA128837; United States / NCI NIH HHS / CA / R01 CA128837-01A2; United States / NIDCR NIH HHS / DE / DE018168-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Antigens, CD11c; 0 / CCL22 protein, human; 0 / Chemokine CCL22; 37758-47-7 / G(M1) Ganglioside; 71012-19-6 / asialo GM1 ganglioside
  • [Other-IDs] NLM/ NIHMS189166; NLM/ PMC2947555
  •  go-up   go-down


16. Robak T, Robak P, Smolewski P: TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs; 2009 Dec;10(12):1383-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
  • TRU-016, under development by Trubion Pharmaceuticals Inc and Facet Biotech Corp, is an intravenously administered anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), as well as for autoimmune and inflammatory diseases.
  • TRU-016 was created by humanizing SMIP-016, a mouse/human chimeric protein that demonstrated antitumor activity against lymphoid malignancies in preclinical studies, including in human B-cell tumor mouse xenograft models.
  • In a phase I/II clinical trial in refractory or relapsed patients with CLL or small lymphocytic lymphoma, TRU-016 was well tolerated, with clinical benefit and a reduced absolute lymphocyte count observed in all cohorts dosed at > 0.1 mg/kg.
  • TRU-016 is a promising therapeutic agent for patients with B-cell lymphoid malignancies, especially patients refractory to standard treatment.
  • [MeSH-major] Antigens, CD / immunology. Antigens, Neoplasm / immunology. Antineoplastic Agents / therapeutic use. Immunoglobulin G / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell / drug therapy. Recombinant Fusion Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19943209.001).
  • [ISSN] 2040-3429
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD37 protein, human; 0 / Immunoglobulin G; 0 / Recombinant Fusion Proteins; 0 / TRU 016; 0 / Tetraspanins
  • [Number-of-references] 73
  •  go-up   go-down


17. Coscia G, Vaccara E, Corvisiero R, Cavazzani P, Ruggieri FG, Taccini G: Fractionated stereotactic radiotherapy: a method to evaluate geometric and dosimetric uncertainties using radiochromic films. Med Phys; 2009 Jul;36(7):2870-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The comparison between the dose distributions measured on films and computed by TPS, after a precise image registration procedure performed by a commercial piece of software (FILMQA, 3cognition LLC (Division of ISP), Wayne, NJ), allowed the authors to measure the repositioning errors, obtaining about 0.5 mm in case of central spherical PTV and about 1.5 mm in case of peripheral irregular PTV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673186.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Reid-Nicholson M, Kavuri S, Ustun C, Crawford J, Nayak-Kapoor A, Ramalingam P: Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation. Cancer; 2008 Oct 25;114(5):333-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation.
  • BACKGROUND: Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin lymphoma that was once believed to occur primarily in the oral cavity of human immunodeficiency virus-positive individuals.
  • The presence of the following was evaluated: cellularity, plasmablastic cells, background necrosis (BN), single-cell necrosis (SCN), lymphoglandular bodies (LGB), tingible-body macrophages (TBM), 3-dimensional clusters/sheets, and cytoplasmic vacuoles.
  • Two patients had the acquired immunodeficiency syndrome and 3 had second non-PBL related malignancies including endometrial carcinoma, lung adenocarcinoma, and small lymphocytic lymphoma.
  • However, although these findings may suggest PBL, a definitive diagnosis requires adjunctive studies including immunohistochemistry and flow cytometry.
  • [MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18683216.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Amagase H, Nance DM: A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized Lycium barbarum (Goji) Juice, GoChi. J Altern Complement Med; 2008 May;14(4):403-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized Lycium barbarum (Goji) Juice, GoChi.
  • BACKGROUND: This randomized, double-blind, placebo-controlled clinical trial is the first study reported from outside China that has examined the general effects of the orally consumed goji berry, Lycium barbarum, as a standardized juice (GoChi; FreeLife International LLC, Phoenix, AZ) to healthy adults for 14 days.
  • METHODS: Based upon the medicinal properties of Lycium barbarum in traditional Asian medicine, we examined by questionnaire subjective ratings (0-5) of general feelings of well-being, neurologic/psychologic traits, gastrointestinal, musculoskeletal, and cardiovascular complaints as well as any adverse effects.
  • CONCLUSIONS: These results clearly indicate that daily consumption of GoChi for 14 days increases subjective feelings of general well-being, and improves neurologic/psychologic performance and gastrointestinal functions.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447631.001).
  • [ISSN] 1075-5535
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 0 / Plant Extracts
  •  go-up   go-down


20. John R, Liao K, Lietz K, Kamdar F, Colvin-Adams M, Boyle A, Miller L, Joyce L: Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J Thorac Cardiovasc Surg; 2007 Aug;134(2):351-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We review our experience with the use of the CentriMag (Levitronix LLC, Waltham, Mass) circulatory support system in such patients whose neurologic status was uncertain.
  • Thus, for our 12 study patients, long-term survival was 75% at 1 month and 62.5% at 1 year.
  • By using this strategy, we avoided the urgent placement of expensive long-term ventricular assist devices in hemodynamically unstable patients with multisystem organ failure whose neurologic status was uncertain until end-organ recovery and excellent hemodynamic stability were achieved with the relatively inexpensive short-term CentriMag circulatory support system.
  • [MeSH-minor] Acute Disease. Analysis of Variance. Decision Making. Heart Transplantation / statistics & numerical data. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Cardiovasc Surg. 2008 Mar;135(3):717; author reply 717-8 [18329513.001]
  • (PMID = 17662772.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Peeters MY, Prins SA, Knibbe CA, Dejongh J, Mathôt RA, Warris C, van Schaik RH, Tibboel D, Danhof M: Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology; 2006 Dec;105(6):1135-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Population pharmacokinetic and pharmacodynamic modeling was performed using NONMEM V (GloboMax LLC, Hanover, MD).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Midazolam .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122576.001).
  • [ISSN] 0003-3022
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypnotics and Sedatives; R60L0SM5BC / Midazolam
  •  go-up   go-down


22. Goldenberg MM: Pharmaceutical approval update. P T; 2008 May;33(5):299-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topics include bendamustine (Treanda) for chronic lymphocytic leukemia, hepatitis B immune globulin (HepaGam B) to prevent hepatitis B infection following liver transplantation, and a fibrin sealant (Artiss) used in skin graft surgery for burn patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561795.001).
  • [ISSN] 1052-1372
  • [Journal-full-title] P & T : a peer-reviewed journal for formulary management
  • [ISO-abbreviation] P T
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2683604
  •  go-up   go-down


23. Morrison VA: Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program; 2007;:332-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of infectious complications in patients with chronic lymphocytic leukemia.
  • Infections remain a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL).
  • The pathogenesis of these complications is related to immune defects inherent to the primary disease as well as to therapy-related immunosuppression.
  • The spectrum of infections seen has evolved with the therapeutic use of purine analogs, which induce specific cellular immune defects, as well as the monoclonal antibodies alemtuzumab and rituximab.
  • This overview will summarize the pathogenesis of infection in patients with CLL as well as the spectrum of infection and approaches to the prophylactic and therapeutic management of these complications.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024648.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


24. Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde DW, Scheinberg DA, Zelenetz AD, Weiss MA: Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol; 2009 Feb 01;27(4):491-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
  • PURPOSE: Modern combination strategies are active in chronic lymphocytic leukemia (CLL) but can have significant myelosuppression and immunosuppression that may require dose attenuation for safety.
  • In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold.
  • PATIENTS AND METHODS: Thirty-six previously untreated CLL patients received therapy with fludarabine 25 mg/m(2) on days 1 through 5 every 4 weeks for six cycles, followed by consolidation with cyclophosphamide 3,000 mg/m(2) administered every 3 weeks for three cycles, followed by consolidation with weekly rituximab 375 mg/m(2) for four cycles.
  • Evaluation for minimal residual disease included flow cytometry and a highly sensitive clonotypic polymerase chain reaction (PCR).
  • The median age was 59 years (range, 37 to 71 years), 61% of patients had high-risk disease, and 58% had unmutated IgV(H) genes.
  • Twenty patients (56%) achieved flow cytometric CRs, and 12 patients (33%) achieved a molecular CR (PCR negative).
  • Patients achieving molecular CRs had an excellent prognosis with a plateau in the response duration curve, and 90% remain in clinical CR at 5 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Sep;14(9):1577-82 [10995003.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1929-36 [11264154.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Diagn Immunol. 1985;3(3):133-8 [3931957.001]
  • [Cites] Leukemia. 1993 Mar;7(3):361-5 [7680398.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • [Cites] Leukemia. 1994 Aug;8(8):1290-3 [8057664.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] Blood. 2006 Jan 15;107(2):742-51 [16179374.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1575-81 [16520464.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [CommentIn] J Clin Oncol. 2009 Feb 1;27(4):479-80 [19075263.001]
  • (PMID = 19075280.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NIAID NIH HHS / AI / R01 AI067823; United States / NCI NIH HHS / CA / R01 CA67823
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2645858
  •  go-up   go-down


25. Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M, Shedden K, Malek SN: Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood; 2008 Sep 1;112(5):1993-2003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia.
  • Chronic lymphocytic leukemia (CLL) has a variable clinical course.
  • Presence of specific genomic aberrations has been shown to impact survival outcomes and can help categorize CLL into clinically distinct subtypes.
  • We studied 178 CLL patients enrolled in a prospective study at the University of Michigan, of whom 139 and 39 were previously untreated and previously treated, respectively.
  • Genomic complexity scores were derived and correlated with the surrogate clinical end points time to first therapy (TTFT) and time to subsequent therapy (TTST): measures of disease aggressiveness and/or therapy efficaciousness.
  • In univariate analysis, progressively increasing complexity scores in previously untreated CLL patients identified patients with short TTFT at high significance levels.
  • Similarly, TTST was significantly shorter in pretreated patients with high as opposed to low genomic complexity.
  • Finally, algorithmic subchromosomal complexity determination was developed, facilitating automation and future routine clinical application of CLL whole-genome analysis.


26. Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G, Bonello L, Horenstein AL, Brennan P, Pepper C, Gaidano G, Malavasi F, Deaglio S: CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia; 2010 May;24(5):958-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.
  • Homing of chronic lymphocytic leukemia (CLL) cells to sites favoring growth, a critical step in disease progression, is principally coordinated by the CXCL12/CXCR4 axis.
  • A cohort of 62 CLL patients was divided into migrating and nonmigrating subsets according to chemotaxis toward CXCL12.
  • Migrating patients phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) proteins more than nonmigrating patients (P<0.0002).
  • CD38 expression was the parameter most strongly associated with heightened CXCL12 signaling (P<0.0001), confirmed by independent statistical approaches.
  • Consistent with this observation, CD38(-) CLL cells in samples with bimodal CD38 expression responded less to CXCL12 than the intact clone (P=0.003).
  • Furthermore, lentivirus-induced de novo expression of CD38 was paralleled by increased responses to CXCL12, as compared with cells infected with a control virus.
  • Blocking anti-CD38 mAbs significantly compromised homing of CLL cells from blood to lymphoid organs in a mouse model.
  • These results indicate that CD38 synergizes with the CXCR4 pathway and support the working hypothesis that migration is a central step in disease progression.
  • [MeSH-major] Antigens, CD38 / physiology. Cell Movement. Chemokine CXCL12 / metabolism. Chemotaxis. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20220774.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CXCL12; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


27. Ruddy KJ, Wu D, Brown JR: Pseudohyperkalemia in chronic lymphocytic leukemia. J Clin Oncol; 2008 Jun 1;26(16):2781-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudohyperkalemia in chronic lymphocytic leukemia.
  • [MeSH-major] Hyperkalemia / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / blood

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509189.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ: MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One; 2009;4(11):e7826
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia.
  • BACKGROUND: Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regulations in the progress of adult leukemia.
  • The role of miRNAs in pediatric leukemia still needs to be established.
  • The purpose of this study was to investigate the aberrantly expressed miRNAs in pediatric acute leukemia and demonstrate miRNA patterns that are pediatric-specific and prognostic parameter-associated.
  • The most highly expressed miRNAs in pediatric ALL were miR-34a, miR-128a, miR-128b, and miR-146a, while the highly expressed miRNAs in pediatric AML were miR-100, miR-125b, miR-335, miR-146a, and miR-99a, which are significantly different from those reported for adult CLL and AML. miR-125b and miR-126 may serve as favorable prognosticators for M3 and M2 patients, respectively.
  • CONCLUSIONS/SIGNIFICANCE: There are existing pediatric-associated and prognostic parameter-associated miRNAs that are independent of cell lineage and could provide therapeutic direction for individual risk-adapted therapy for pediatric leukemia patients.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Leukemia / diagnosis. Leukemia / pathology. MicroRNAs

  • MedlinePlus Health Information. consumer health - Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] J Pediatr (Rio J). 2003 Mar-Apr;79(2):149-58 [14502336.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):167-9 [14695998.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Nature. 2005 Mar 17;434(7031):338-45 [15735639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1768-71 [16251533.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):167-73 [16616063.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2825-32 [18089852.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3183-9 [18187662.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50 [18308931.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 [18832181.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2499-506 [18936236.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Leukemia. 2009 Feb;23(2):313-22 [18923441.001]
  • [Cites] Dev Biol. 1999 Dec 15;216(2):671-80 [10642801.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):179-81 [12525506.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • (PMID = 19915715.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2773830
  •  go-up   go-down


29. Dennison JB, Ayres ML, Kaluarachchi K, Plunkett W, Gandhi V: Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. J Biol Chem; 2010 Mar 12;285(11):8022-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 8-Chloroadenosine (8-Cl-Ado) is a ribosyl nucleoside analog currently in phase I testing for the treatment of chronic lymphocytic leukemia (CLL).
  • In the current study with four mantle cell lymphoma cell lines, we report a new major metabolic pathway for 8-Cl-Ado intracellular metabolism, the formation of succinyl-8-chloro-adenosine (S-8-Cl-Ado) and its monophosphate (S-8-Cl-AMP).
  • Consistent with fumarate as a required substrate for formation of succinyl-8-Cl-adenylate metabolites, the S-8-Cl-adenylate concentrations in multiple cell lines were associated with fumarate loss.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SUCCINIC ACID .
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):223-8 [10617608.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jun;121(2):355-64 [19641990.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 2000 Aug 18;745(2):421-30 [11043760.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5474-9 [11454694.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):406-10 [11865300.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Aug;50(2):85-94 [12172971.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7968-74 [14633728.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):40405-11 [15265873.001]
  • [Cites] Clin Chim Acta. 1985 Jun 14;148(3):185-96 [4042353.001]
  • [Cites] Anal Biochem. 1991 Mar 2;193(2):287-91 [1872474.001]
  • [Cites] J Inherit Metab Dis. 1997 Jun;20(2):193-202 [9211192.001]
  • [Cites] J Biol Chem. 1956 Sep;222(1):17-30 [13366975.001]
  • [Cites] Mol Cancer Ther. 2004 Nov;3(11):1411-20 [15542780.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):569-77 [15827330.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4455-62 [15718423.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):143-53 [16098467.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4675-82 [16892081.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Aug;91(8):3071-5 [16757530.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4524-32 [17182618.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9913-20 [17942923.001]
  • [Cites] Mol Cell Proteomics. 2009 Jan;8(1):70-85 [18723843.001]
  • [Cites] Mol Cancer Ther. 2009 Mar;8(3):626-35 [19276158.001]
  • [Cites] Diabetes Obes Metab. 2009 May;11 Suppl 2:3-8 [19385978.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3297-302 [19487376.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4080-90 [19470762.001]
  • [Cites] Biochem Pharmacol. 2009 Sep 15;78(6):583-91 [19477165.001]
  • [Cites] Br J Haematol. 2009 Nov;147(3):297-307 [19709085.001]
  • [Cites] J Inherit Metab Dis. 2000 Jun;23(4):371-4 [10896297.001]
  • (PMID = 20064937.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA085915; United States / NCI NIH HHS / CA / CA 85915; United States / NCI NIH HHS / CA / CA136411; United States / NCI NIH HHS / CA / P50 CA136411
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fumarates; 0 / Hypoglycemic Agents; 0 / Oligomycins; 0 / Purines; 0 / Uncoupling Agents; 146-77-0 / 2-Chloroadenosine; 23583-48-4 / 8-Bromo Cyclic Adenosine Monophosphate; 34408-14-5 / 8-chloroadenosine; 41941-56-4 / 8-chloro-cyclic adenosine monophosphate; 9100L32L2N / Metformin; AB6MNQ6J6L / Succinic Acid
  • [Other-IDs] NLM/ PMC2832953
  •  go-up   go-down


30. Sweeney N, Gallagher WM, Müller-Bunz H, Pampillón C, Strohfeldt K, Tacke M: Heteroaryl substituted titanocenes as potential anti-cancer drugs. J Inorg Biochem; 2006 Sep;100(9):1479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When titanocenes 3a-c were tested against pig kidney (LLC-PK) cells inhibitory concentrations (IC(50)) of 1.6x10(-4)M, 1.5x10(-4)M and 9.1x10(-4)M, respectively, were observed.
  • These values represent improved cytotoxicity against LLC-PK, when compared to their corresponding ansa substituted analogues and also in comparison to unsubstituted titanocene dichloride.
  • [MeSH-minor] Animals. Cell Line. Cell Survival. Drug Evaluation, Preclinical. Molecular Conformation. Molecular Structure. Swine

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764931.001).
  • [ISSN] 0162-0134
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organometallic Compounds; 1271-29-0 / titanocene
  •  go-up   go-down


31. Yu Z, Sun B, Kantarjian HM, Keating MJ, Amin HM, Sun X: Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. Leuk Lymphoma; 2008 Apr;49(4):751-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators.
  • Chronic lymphocytic leukemia (CLL) cells rapidly undergo apoptosis when cultured in vitro, which contrasts with their prolonged survival in vivo.
  • Multiple cytokines and cytokine receptors are believed to work together to regulate the survival of CLL cells.
  • The aim of the current study was to measure the endogenous expression and secretion of cytokines and cytokine receptors in CLL cells when exogenous cytokines are minimized.
  • We demonstrated that the intracellular and secreted levels of 174 cytokines and cytokine receptors of purified CLL B-cells were not significantly different from those of normal B-cells except for the secreted levels of IL-6 and eotaxin.
  • IL-6 was 3.0 times lower (p = 0.038) whereas eotaxin was 2.2 times higher (p = 0.027) in CLL conditioned medium than in normal B-cell conditioned medium.
  • Our results suggest that, except for IL-6 and eotaxin, CLL B-cells and their normal counterparts produce and secrete similar amounts of cytokines and cytokine receptors in vitro.
  • [MeSH-major] Cytokines / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Receptors, Cytokine / analysis
  • [MeSH-minor] Adult. Aged. B-Lymphocytes / secretion. Case-Control Studies. Cells, Cultured. Chemokine CCL11 / analysis. Chemokine CCL11 / secretion. Female. Humans. Interleukin-6 / analysis. Interleukin-6 / secretion. Male. Middle Aged. Prognosis. Proteomics / methods

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398743.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCL11 protein, human; 0 / Chemokine CCL11; 0 / Cytokines; 0 / Interleukin-6; 0 / Receptors, Cytokine
  •  go-up   go-down


32. Lundin J, Karlsson C, Celsing F: Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia. Med Oncol; 2006;23(1):137-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.
  • B-cell chronic lymphocytic leukemia (B-CLL) is the most common cause of autoimmune hemolytic anemia (AIHA), and a subgroup of these patients who develop both these conditions fail to respond to corticosteroids, cytotoxic drugs, splenectomy, and iv immunoglobulins.
  • Alemtuzumab is a humanized anti-CD52 monoclonal antibody that is an effective therapy for B-CLL, mycosis fungoides, and T-cell prolymphocytic leukemia.
  • Here we present a case report of a 78-yr-old woman with B-CLL and progressive life-threatening AIHA with hemoglobin count 5.5 g/dL following fludarabine treatment, who was treated successfully with alemtuzumab.
  • We conclude that alemtuzumab may be indicated for the treatment of AIHA in B-CLL patients who have failed other treatments.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / drug therapy. Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / complications

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 May;16(5):1885-9 [9586905.001]
  • [Cites] Br J Haematol. 1986 Nov;64(3):479-86 [3539172.001]
  • [Cites] Blood. 1993 Aug 1;82(3):807-12 [7687895.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):151-3 [8611450.001]
  • [Cites] Blood. 1996 May 1;87(9):3869-76 [8611714.001]
  • [Cites] Eur J Haematol. 2003 May;70(5):319-21 [12694169.001]
  • [Cites] Hematol Cell Ther. 1997 Nov;39 Suppl 1:S41-4 [9471060.001]
  • [Cites] Semin Hematol. 1992 Jan;29(1):64-74 [1570545.001]
  • [Cites] Mol Hum Reprod. 1996 Mar;2(3):177-84 [9238677.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):1007-11 [12148879.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):891-8 [11564082.001]
  • [Cites] Blood. 1989 May 1;73(6):1431-9 [2713487.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):278-81 [14531909.001]
  • [Cites] Blood. 2000 May 1;95(9):2786-92 [10779422.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):6088-99 [7890742.001]
  • [Cites] Immunology. 1998 Nov;95(3):427-36 [9824507.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):80-97 [9482530.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):34-41 [9482525.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Nature. 1988 Mar 24;332(6162):323-7 [3127726.001]
  • [Cites] Semin Hematol. 1992 Jan;29(1):3-12 [1570541.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • [Cites] Ann Oncol. 1992 Feb;3(2):171-2 [1606091.001]
  • (PMID = 16645240.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


33. Jaksić O, Kardum-Skelin I, Jaksić B: Chronic lymphocytic leukemia: insights from lymph nodes & bone marrow and clinical perspectives. Coll Antropol; 2010 Mar;34(1):309-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia: insights from lymph nodes & bone marrow and clinical perspectives.
  • B-cell chronic lymphocytic leukemia (B-CLL) is characterized by highly variable distribution of tumor mass between peripheral blood, bone marrow and lymphoid organs which is important for staging, classification and prognosis.
  • These clinical findings with novel data about importance of B-cell receptor and its stimulation with the support of microenvironment indicate important role of tissues (lymphoid organs and bone marrow) in the pathogenesis of B-CLL.
  • Here is presented the novel approach of simultaneous characterization of B-CLL cells form peripheral blood, bone marrow and lymph nodes by flow cytometry and immunocytochemistry, defining inter- and intraclonal diversity with respect to various molecules.
  • A number of interesting significant interactions have been discovered, pointing to the important role of neoplastic cell microenvironment.
  • These may in addition to insights in pathogenesis and roles of different microenvironments add to diagnosis, prognosis and treatment of B-CLL patients.
  • [MeSH-major] Bone Marrow / pathology. Flow Cytometry. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / physiopathology. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432765.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Croatia
  • [Number-of-references] 59
  •  go-up   go-down


34. Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszyńska A, Schmitt M: Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia; 2005 Sep;19(9):1621-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.
  • Recently, immunotherapies with allogeneic dendritic cells (DCs) pulsed with tumor antigens to generate specific T-cell responses have been tested in clinical trials for patients with solid tumors.
  • This is the first report on a clinical vaccination study with DCs for patients with B-cell chronic lymphocytic leukemia (B-CLL).
  • The potential of allogeneic DCs pulsed ex vivo with tumor cell lysates or apoptotic bodies to stimulate antitumor immunity in patients with B-CLL in early stages was evaluated.
  • In one patient, a significant increase of specific cytotoxic T lymphocytes against RHAMM/CD168, a recently characterized leukemia-associated antigen, could be detected after DC vaccination.
  • Taken together, the study demonstrated that DC vaccination in CLL patients is feasible and safe.
  • [MeSH-major] Apoptosis / immunology. Cancer Vaccines / therapeutic use. Dendritic Cells / immunology. Immunotherapy / methods. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Neoplasm Proteins / immunology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990861.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Cancer Vaccines; 0 / Extracellular Matrix Proteins; 0 / Neoplasm Proteins; 0 / hyaluronan-mediated motility receptor
  •  go-up   go-down


35. Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, Damschroder-Williams P, Du J, Zhang L, Manji HK: The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci; 2005 May 4;25(18):4493-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers.
  • Increasing data suggest that impairments of cellular plasticity/resilience underlie the pathophysiology of bipolar disorder.
  • A series of microarray studies with validating criteria have recently revealed a common, novel target for the long-term actions of the structurally highly dissimilar mood stabilizers lithium and valproate: BAG-1 [BCL-2 (B-cell CLL/lymphoma 2)-associated athanogene].
  • Chronic administration of both agents at therapeutic doses increased the expression of BAG-1 in rat hippocampus.
  • Furthermore, these findings were validated at the protein level, and the effects were seen in a time frame consistent with therapeutic effects and were specific for mood stabilizers.
  • Furthermore, small interfering RNA studies showed that these inhibitory effects on GR activity were mediated, at least in part, through BAG-1.
  • The observation that BAG-1 inhibits glucocorticoid activation suggests that mood stabilizers may counteract the deleterious effects of hypercortisolemia seen in bipolar disorder by upregulating BAG-1.
  • Additionally, these studies suggest that regulation of GR-mediated plasticity may play a role in the treatment of bipolar disorder and raise the possibility that agents affecting BAG-1 more directly may represent novel therapies for this devastating illness.
  • [MeSH-minor] Alkaline Phosphatase / genetics. Alkaline Phosphatase / metabolism. Animals. Behavior, Animal. Blotting, Western / methods. Cell Line, Tumor. Dexamethasone / pharmacology. Dose-Response Relationship, Drug. Drug Interactions. Gene Expression / drug effects. Humans. Immunohistochemistry / methods. Indoles / metabolism. Male. Molecular Weight. Neuroblastoma. RNA, Small Interfering / pharmacology. Rats. Rats, Wistar. Receptors, Glucocorticoid / metabolism. Time Factors. Transfection / methods

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. LITHIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15872096.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimanic Agents; 0 / BCL2-associated athanogene 1 protein; 0 / DNA-Binding Proteins; 0 / Indoles; 0 / RNA, Small Interfering; 0 / Receptors, Glucocorticoid; 0 / Transcription Factors; 47165-04-8 / DAPI; 614OI1Z5WI / Valproic Acid; 7S5I7G3JQL / Dexamethasone; 9FN79X2M3F / Lithium; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


36. Nunes P, Hasler U, McKee M, Lu HA, Bouley R, Brown D: A fluorimetry-based ssYFP secretion assay to monitor vasopressin-induced exocytosis in LLC-PK1 cells expressing aquaporin-2. Am J Physiol Cell Physiol; 2008 Dec;295(6):C1476-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A fluorimetry-based ssYFP secretion assay to monitor vasopressin-induced exocytosis in LLC-PK1 cells expressing aquaporin-2.
  • Vasopressin (VP)-induced exocytosis was dissected in native and aquaporin-2 (AQP2)-expressing renal LLC-PK(1) cells by a fluorimetric exocytosis assay based on soluble secreted yellow fluorescent protein (ssYFP).
  • Fluorimetry and Western blot analysis demonstrated similar constitutive ssYFP secretion in native LLC-PK(1) and AQP2-expressing cells.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Renal Physiol. 2005 Jun;288(6):F1103-12 [15644488.001]
  • [Cites] J Biol Chem. 2008 Sep 26;283(39):26643-61 [18664568.001]
  • [Cites] Mol Cell Proteomics. 2005 Aug;4(8):1095-106 [15905145.001]
  • [Cites] Histochem Cell Biol. 2005 Jul;124(1):1-12 [16049696.001]
  • [Cites] J Am Soc Nephrol. 2005 Oct;16(10):2881-9 [16093449.001]
  • [Cites] J Cell Biol. 2005 Sep 26;170(7):1113-25 [16186257.001]
  • [Cites] Traffic. 2005 Dec;6(12):1142-56 [16262725.001]
  • [Cites] Nephrol Dial Transplant. 2000;15 Suppl 6:21-2 [11143977.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Dec;281(6):F1092-101 [11704560.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):205-44 [11773613.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10379-86 [11782489.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Jun;282(6):F998-1011 [11997316.001]
  • [Cites] J Biol Chem. 2003 Jan 10;278(2):1101-7 [12374804.001]
  • [Cites] EMBO Rep. 2003 Jan;4(1):88-93 [12524527.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 May;284(5):F893-901 [12676734.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Oct;285(4):C750-62 [12801889.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Feb;286(2):F233-43 [14519593.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Feb;5(2):121-32 [15040445.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13368-73 [15326289.001]
  • [Cites] Mol Cell Biol. 1985 Dec;5(12):3610-6 [3915782.001]
  • [Cites] Am J Physiol. 1993 Aug;265(2 Pt 2):F214-24 [8396343.001]
  • [Cites] Experientia. 1994 Nov 30;50(11-12):1012-20 [7988659.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7212-6 [7543677.001]
  • [Cites] EMBO J. 1996 Feb 1;15(3):510-9 [8599934.001]
  • [Cites] J Biol Chem. 1997 Jun 6;272(23):14800-4 [9169447.001]
  • [Cites] Am J Physiol. 1997 Jun;272(6 Pt 2):F817-22 [9227644.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Feb;278(2):F317-26 [10662736.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Mar;278(3):F388-94 [10710543.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jan;278(1):F29-42 [10644653.001]
  • [Cites] J Cell Sci. 2000 Jun;113 ( Pt 11):1985-92 [10806109.001]
  • [Cites] J Clin Invest. 2000 Nov;106(9):1115-26 [11067864.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36839-46 [10973964.001]
  • [Cites] Plant Cell Physiol. 2000 Sep;41(9):993-1001 [11100771.001]
  • [Cites] Nature. 1997 Sep 4;389(6646):81-5 [9288971.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):133-42 [9352218.001]
  • [Cites] Curr Opin Neurobiol. 1997 Oct;7(5):631-9 [9384543.001]
  • [Cites] J Membr Biol. 1998 Jan 15;161(2):141-9 [9435270.001]
  • [Cites] Biochem J. 1998 Apr 15;331 ( Pt 2):669-75 [9531511.001]
  • [Cites] J Cell Biol. 1998 Dec 14;143(6):1485-503 [9852146.001]
  • [Cites] J Am Soc Nephrol. 1999 Jul;10(7):1416-29 [10405197.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):46969-80 [15319442.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 May;288(5):F930-8 [15625084.001]
  • [Cites] Endocrinology. 2005 Dec;146(12):5063-70 [16150901.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Jan;290(1):F177-87 [15985652.001]
  • [Cites] Biol Cell. 2006 Apr;98(4):215-32 [16563128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7159-64 [16641100.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1276-86 [16418206.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Jul;291(1):F246-53 [16449354.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Oct;291(4):F882-90 [16684923.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:439-55 [16824007.001]
  • [Cites] Traffic. 2007 Feb;8(2):110-23 [17156409.001]
  • [Cites] PLoS Comput Biol. 2007 Mar 23;3(3):e57 [17381238.001]
  • [Cites] Nat Rev Genet. 2007 Jul;8(7):533-43 [17572691.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1129-38 [17626240.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28721-32 [17636261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16696-701 [17940053.001]
  • [Cites] Neuron. 2007 Nov 21;56(4):657-69 [18031683.001]
  • [Cites] Semin Nephrol. 2008 May;28(3):266-78 [18519087.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2008 Sep;17(5):491-8 [18695390.001]
  • [Cites] J Cell Biol. 2008 Aug 11;182(3):587-601 [18678705.001]
  • [Cites] J Am Soc Nephrol. 2005 Jun;16(6):1571-82 [15843469.001]
  • (PMID = 18799651.001).
  • [ISSN] 0363-6143
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK-38452; United States / NIDDK NIH HHS / DK / DK-43341; United States / NIDDK NIH HHS / DK / DK-57521; United States / NIDDK NIH HHS / DK / K08 DK-075940-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aquaporin 2; 0 / Luminescent Proteins; 11000-17-2 / Vasopressins
  • [Other-IDs] NLM/ PMC2603565
  •  go-up   go-down


37. Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol; 2006 May 20;24(15):2337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
  • PURPOSE: Treatment with alemtuzumab has resulted in negative responses for minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL).
  • In a prior analysis we demonstrated that it is possible to achieved MRD negativity, as assessed by polyclonality of immunoglobulin heavy chain after consolidation with alemtuzumab.
  • This phase II study evaluated 34 patients with CLL who received alemtuzumab consolidation in an effort to improve the quality of their response to fludarabine-based induction.
  • Subsequent peripheral blood stem-cell (PBSC) collection and transplantation, tolerability, and pharmacokinetics also were assessed.
  • CONCLUSION: Subcutaneously administered alemtuzumab was effective, safe, and well tolerated as consolidation therapy in patients with CLL who responded to fludarabine induction therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Peripheral Blood Stem Cell Transplantation


38. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ: Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol; 2007 Mar;136(6):800-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
  • Immune anaemias (IA) [auto-immune haemolytic anaemia (AIHA) and pure red cell aplasia (PRCA)] are complications of chronic lymphocytic leukaemia (CLL).
  • Additional markers of haemolysis (indirect hyperbilirubinaemia, reticulocytosis, low haptoglobin and elevated lactate dehydrogenase levels) confirmed the presence of AIHA in these patients.
  • Thus, the incidence of IA among CLL patients treated with FCR was comparable with historical rates.
  • The diagnosis of AIHA can be considered even if the DAT is negative.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / etiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Red-Cell Aplasia, Pure / etiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2007 Nov;139(4):622-3 [17979948.001]
  • (PMID = 17341265.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Glucocorticoids; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


39. Paydas S, Tanriverdi K, Yavuz S, Seydaoglu G: PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. Leuk Res; 2007 Mar;31(3):365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
  • The aim of this study is to determine the frequency and the clinical importance of PRAME expression in chronic myeloid leukemia (CML)/chronic myeloproliferative disorders (CMPD) and chronic lymphocytic leukemia (CLL).
  • PRAME mRNA was measured by real time RT-PCR in 88 cases with chronic leukemia (CL) and 42 controls.
  • Seventy cases had CML/CMPD (56 had chronic phase (CP)-14 had accelerated/blastic phase disease (AP/BP) and 18 cases had CLL (11 had early stage (Rai 0-I-II) and 7 had late stage (Rai III-IV).
  • Twenty-four of 70 (34%) cases with CML/CMPD and 5 of 18 (28%) cases with CLL showed PRAME expression.
  • PRAME (+) and PRAME (-) cases were not different for age, Hb, Hct, WBC count, platelet count, stage of the disease and response to therapy.
  • PRAME was monitorised in eight cases during follow-up: in three cases PRAME was negative at CP and expression developed at the AP/BP disease.
  • PRAME mRNA may be a useful marker to detect the minimal residual disease (MRD) and to determine the response to therapy in CLs.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Myeloproliferative Disorders / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chronic Disease. Disease Progression. Female. Follow-Up Studies. Gene Expression Profiling. Humans. Male. Middle Aged. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16914202.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / PRAME protein, human; 0 / RNA, Messenger
  •  go-up   go-down


40. Kuramochi K, Matsui R, Matsubara Y, Nakai J, Sunoki T, Arai S, Nagata S, Nagahara Y, Mizushina Y, Ikekita M, Kobayashi S: Apoptosis-inducing effect of epolactaene derivatives on BALL-1 cells. Bioorg Med Chem; 2006 Apr 1;14(7):2151-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epolactaene, a neuritogenic compound in human neuroblastoma SH-SY5Y, induces apoptosis in a human leukemia B-cell line, BALL-1.
  • The alpha-acyl-alpha,beta-epoxy-gamma-lactam moiety as well as the hydrophobicity derived from the long alkyl side chain are both important for activity.
  • [MeSH-major] Apoptosis / drug effects. Leukemia, B-Cell / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Drug Screening Assays, Antitumor. Epoxy Compounds / chemical synthesis. Epoxy Compounds / chemistry. Epoxy Compounds / pharmacology. Humans. Hydrolysis. Molecular Structure. Polyenes / chemical synthesis. Polyenes / chemistry. Polyenes / pharmacology. Stereoisomerism. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298530.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Epoxy Compounds; 0 / Polyenes; 0 / epolactaene
  •  go-up   go-down


41. Gutiérrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Fermiñán E, Arcos MJ, Sánchez ML, Hernández JM, San Miguel JF: Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia; 2007 Mar;21(3):541-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.
  • The tumoral clone of Waldenström's macroglobulinemia (WM) shows a wide morphological heterogeneity, which ranges from B lymphocytes (BL) to plasma cells (PC).
  • By means of genome-wide expression profiling we have been able to identify genes exclusively deregulated in BL and PC from WM, but with a similar expression pattern in their corresponding cell counterparts from chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), as well as normal individuals.
  • The differentially expressed genes have important functions in B-cell differentiation and oncogenesis.
  • Thus, two of the genes downregulated in WM-BL were IL4R, which plays a relevant role in CLL B-cell survival, and BACH2, which participates in the development of class-switched PC.
  • A set of four genes was able to discriminate clonal BL from WM and CLL: LEF1 (WNT/beta-catenin pathway), MARCKS, ATXN1 and FMOD.
  • We also found deregulation of genes involved in plasma cell differentiation such as PAX5, which was overexpressed in WM-PC, and IRF4 and BLIMP1, which were underexpressed.
  • In summary, these results indicate that both PC and BL from WM are genetically different from the MM and CLL cell counterpart.
  • [MeSH-major] B-Lymphocytes / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Multiple Myeloma / pathology. Plasma Cells / metabolism. Waldenstrom Macroglobulinemia / pathology


42. Buhl AM, Jurlander J, Geisler CH, Pedersen LB, Andersen MK, Josefsson P, Petersen JH, Leffers H: CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol; 2006 Jun;76(6):455-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia.
  • OBJECTIVES: Chronic lymphocytic leukemia (CLL) is an incurable disease with a highly variable clinical course.
  • IgV(H) mutational status, chromosomal aberrations, CD38 expression and ZAP-70 expression are prognostic markers in CLL, however, they are not exclusively confined to this disease.
  • We recently identified a novel CLL-specific gene (CLL upregulated gene1, CLLU1) that is exclusively upregulated in CLL cells.
  • Here we describe our evaluation of the prognostic significance of CLLU1 in CLL.
  • METHODS: A cohort of 59 previously untreated CLL patients was studied.
  • RESULTS: Analyzed as a continuous, quantitative parameter CLLU1 levels significantly predicted time from diagnosis to initiation of therapy (P < or = 0.0003) Analyzed as a categorical parameter, by segregation of the patients into groups with cDNA1 or CDS expression above or below the median, the CLLU1 levels significantly predicted time from diagnosis to initiation of therapy (P = 0.001) and predicted overall survival with borderline significance (P < or = 0.05).
  • Patient stratification according to clinical stage, cytogenetics, IgV(H) mutational status, ZAP-70 and CD38, demonstrated significantly increased CLLU1 expression in all investigated CLL poor risk groups.
  • CONCLUSIONS: CLLU1 is the first identified CLL specific gene.
  • The CLLU1 mRNA expression level can predict time to initiation of treatment and survival in CLL patients.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Neoplasm Proteins / biosynthesis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Haematol. 2006 Aug;77(2):177; author reply 178 [16856913.001]
  • (PMID = 16529606.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLLU1 protein, human; 0 / DNA, Complementary; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


43. Chae HW, Kim IW, Jin HE, Kim DD, Chung SJ, Shim CK: Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine. Arch Pharm Res; 2008 Jan;31(1):103-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to examine the effect of ion-pair complexation with endogenous bile salts on the transport of a quarternary ammonium organic cationic (OC) drug, berberine, across the Caco-2 and LLC-PK1 cell monolayers.
  • Similar results were observed for the transport of berberine across the LLC-PK1 cells.
  • These results suggest that an efflux transporter, probably P-gp, is involved in the Caco-2 cell transport.
  • The apparent partition coefficient (APC) of berberine between n-octanol and a phosphate buffer (pH 7.4) was increased by the presence of an organic anion (OA), taurodeoxycholate (TDC, a bile salt), suggesting the formation of a lipophilic ion-pair complex between an OC (berberine) and an OA (TDC).
  • Despite the ion-pair complexation, however, the BL-AP transport of berberine across the Caco-2 and LLC-PK1 cells was not altered by the cis-presence of bile salts or the rat bile juice.
  • This is consistent with the reportedly unaltered secretory transport of a quarternary ammonium compound, tributylmethylammonium (TBuMA), across the Caco-2 cell monolayers in the cis-presence of bile salts or the rat bile juice, but not with our previous report in which the secretory transport of TBuMA across the LLC-PK1 cell was increased in the cis-presence of TDC.
  • Therefore, the effect of ion-pair formation with the bile components or bile salts on the secretory transport of OCs appears to depend on the molecular properties of OCs (e.g., molecular weight, lipophilicity and affinity to relevant transporters) and the characteristics of cell strains (e.g., expression and contribution of responsible transporters to the transport).
  • [MeSH-minor] Animals. Biological Transport, Active. Caco-2 Cells. Cell Membrane / metabolism. Chemistry, Physical. Chromatography, High Pressure Liquid. Data Interpretation, Statistical. Humans. LLC-PK1 Cells. P-Glycoprotein / antagonists & inhibitors. P-Glycoprotein / metabolism. Physicochemical Phenomena. Solubility. Swine. Taurodeoxycholic Acid / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277615.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / P-Glycoprotein; 0I8Y3P32UF / Berberine; 516-50-7 / Taurodeoxycholic Acid
  •  go-up   go-down


44. Moore DA, Fuller B, Hazzan M, Jones JW: Development of a security vulnerability assessment process for the RAMCAP chemical sector. J Hazard Mater; 2007 Apr 11;142(3):689-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a security vulnerability assessment process for the RAMCAP chemical sector.
  • The Department of Homeland Security (DHS), Directorate of Information Analysis & Infrastructure Protection (IAIP), Protective Services Division (PSD), contracted the American Society of Mechanical Engineers Innovative Technologies Institute, LLC (ASME ITI, LLC) to develop guidance on Risk Analysis and Management for Critical Asset Protection (RAMCAP).
  • AcuTech Consulting Group (AcuTech) has been contracted by ASME ITI, LLC, to provide assistance by facilitating the development of sector-specific guidance on vulnerability analysis and management for critical asset protection for the chemical manufacturing, petroleum refining, and liquefied natural gas (LNG) sectors.
  • This activity involves two key tasks for these three sectors: Development of a screening to supplement DHS understanding of the assets that are important to protect against terrorist attack and to prioritize the activities.
  • Development of a standard security vulnerability analysis (SVA) framework for the analysis of consequences, vulnerabilities, and threats.
  • This project involves the cooperative effort of numerous leading industrial companies, industry trade associations, professional societies, and security and safety consultants representative of those sectors.
  • Jones is the chief technology officer for ASME-ITI, LLC for RAMCAP.

  • MedlinePlus Health Information. consumer health - Disaster Preparation and Recovery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920260.001).
  • [ISSN] 0304-3894
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Hazardous Substances
  •  go-up   go-down


45. Fernàndez V, Jares P, Salaverria I, Giné E, Beà S, Aymerich M, Colomer D, Villamor N, Bosch F, Montserrat E, Campo E: Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica; 2008 Jan;93(1):132-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia.
  • The biologic mechanisms involved in the clinical progression from early stages of patients with chronic lymphocytic leukemia (CLL) are not well known.
  • We investigated sequential samples from 16 untreated CLL patients obtained at diagnosis in early stage and after progression before treatment.
  • One patient had a p16 (INK4a) homozygous deletion at diagnosis and progression, and 3 patients acquired a p53 mutation, gains of 5q21-q23 and 11pter-p14, and a gain of chromosome 12 respectively, during the progression of the disease.
  • Gene expression profile analysis showed a significant modulation of 58 genes with a particular downregulation of genes that are inhibitors of cell adhesion and motility.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genome. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Disease Progression. Female. Genes, p53 / genetics. Humans. Male. Middle Aged. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166798.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


46. Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M, Helfrich H, Mertens D, Dohner H, Stilgenbauer S: Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma; 2009 Mar;50(3):510-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.
  • The importance of studying p53 pathway defects in chronic lymphocytic leukemia (CLL) has been promoted by the demonstration of the fundamentally different clinical course of patients with 17p deletion.
  • The observation of resistance to chemotherapy and mutation of the remaining TP53 allele explain the clinical presentation of CLL with 17p deletion.
  • In addition, other principal components of the DNA damage pathway reportedly are de-regulated by mutation (ATM), deletion (ATM) or potentially more complex down-regulation (miR-34a) in CLL.
  • Nonetheless, challenges remain because we can only explain resistance in a proportion of the cases that are resistant to first line treatment.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347737.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 12
  •  go-up   go-down


47. Ticchioni M, Essafi M, Jeandel PY, Davi F, Cassuto JP, Deckert M, Bernard A: Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene; 2007 Nov 1;26(50):7081-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a.
  • B-chronic lymphocytic leukemia (B-CLL) cell is characterized by the accumulation of long-lived CD5+ B lymphocytes, whose survival in vivo is in part dependent on exogenous factors such as cytokines and/or extracellular matrix proteins.
  • Homeostatic chemokines are critical mediators of lymphoid cell trafficking.
  • However, how they function in cell signaling and survival remains ill-defined.
  • In this study, we have investigated the role of the homeostatic chemokines, CXCL12, CCL21, CCL19 and CXCL13, in B-CLL cell survival.
  • Using primary leukemic cells isolated from 26 patients, we observed that each chemokine enhances cell survival.
  • Moreover, using a constitutively active mutated form of FOXO3a or siRNAs against FOXO3a in transfection experiments performed in primary B-CLL cells, we directly demonstrated the critical role of FOXO3a in both spontaneous and chemokine-induced B-CLL cell survival.
  • Overall, our data support the notion that homeostatic chemokines contribute to B-CLL resistance to cell death through inactivation of the transcription factor FOXO3a, which may represent a novel therapeutic target in this hematopoietic malignancy.
  • [MeSH-major] Chemokines / physiology. Forkhead Transcription Factors / antagonists & inhibitors. Homeostasis / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Apoptosis / genetics. Apoptosis / immunology. Cell Death / genetics. Cell Death / immunology. Cell Survival / immunology. Female. Humans. Male. Middle Aged. Transcriptional Activation / genetics. Transcriptional Activation / immunology


48. Sureda NC, Bosch MP, Kurpis M, Ruiz Lascano A: [Leukaemia cutis: clinical manifestation of chronic lymphocytic leukaemia relapse]. Rev Fac Cien Med Univ Nac Cordoba; 2007;64(1):42-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leukaemia cutis: clinical manifestation of chronic lymphocytic leukaemia relapse].
  • [Transliterated title] Leucemia cutis: expresión clínica de recaída de leucemia linfocítica crónica.
  • We present a 71 year old male patient with previous records of Chronic Lymphocytic Leukaemia who presented with a tumoral skin lesion.
  • Histological and immunohistochemical studies confirmed the Leukaemia Cutis diagnosis.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemic Infiltration / pathology. Skin / pathology

  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426096.001).
  • [ISSN] 0014-6722
  • [Journal-full-title] Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina)
  • [ISO-abbreviation] Rev Fac Cien Med Univ Nac Cordoba
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 18D0SL7309 / Chlorambucil
  •  go-up   go-down


49. Wilhelm C, Neubauer A, Brendel C: Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied. Cytometry B Clin Cytom; 2006 Jul 15;70(4):242-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied.
  • BACKGROUND: Recent studies have identified ZAP-70 expression status as an excellent prognostic parameter in chronic lymphocytic leukemia (CLL).
  • METHODS: One hundred and one patients with B-CLL were analyzed employing a directly labeled alexa-fluor-488-ZAP-70-antibody.
  • RESULTS: Applying either T-/NK-cell isotype or healthy control analysis strategies on patient samples that were processed in parallel revealed discrepant results in 48% (12/25) of all cases.
  • Taken together with the 74 B-CLL patients, who were analyzed with regard to average reference values, disconcordant results were obtained in 58% of the samples.
  • We demonstrate that high variances in ZAP-70 T-/NK-cell staining within B-CLL patients, paired with a close proximity of ZAP-70 B-cell values to the suggested cut-off levels, may lead to interpretation difficulties of ZAP-70 status.
  • Further standardization is required before ZAP-70 can be used as a reliable prognostic parameter in immunophenotyping of B-CLL.
  • [MeSH-major] Flow Cytometry / methods. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. ZAP-70 Protein-Tyrosine Kinase / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / immunology. Humans. Immunophenotyping. Kaplan-Meier Estimate. Killer Cells, Natural / immunology. Middle Aged. Reference Values. Reproducibility of Results. Survival Rate. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 International Society for Analytical Cytology.
  • (PMID = 16906574.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


50. Agrawal SG, Liu FT, Wiseman C, Shirali S, Liu H, Lillington D, Du MQ, Syndercombe-Court D, Newland AC, Gribben JG, Jia L: Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood; 2008 Mar 1;111(5):2790-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia.
  • Many biologic markers are associated with poor prognosis in chronic lymphocytic leukemia (CLL), but their mechanistic role remains unclear.
  • Using a Bax degradation activity (BDA) assay, CLL cells were found to show variable Bax instability.
  • However, BDA did not correlate with Bax protein levels: BDA positive and negative cases had high and low baseline Bax levels.
  • Patients with BDA positive cells had a shorter median overall survival (OS; 126 months vs not reached, P = .011) and time to first treatment (16 vs 156 months, P = .029) than BDA negative cases.
  • Dual BDA and ZAP-70 positivity had a median OS of 84 months (P = .012).
  • The BDA assay measures the intrinsic ubiquitin/proteasome activity of CLL cells and dynamic changes in Bax protein levels over time.
  • Mechanistically, Bax instability may represent a final common pathway for disparate prognostic markers, as well as being itself an indicator of poor prognosis.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Proteasome Endopeptidase Complex / metabolism. Protein Processing, Post-Translational. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160666.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / bcl-2-Associated X Protein; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


51. Kiran S, Cocco P, Mannetje A, Satta G, D'Andrea I, Becker N, de Sanjosé S, Foretova L, Staines A, Kleefeld S, Maynadié M, Nieters A, Brennan P, Boffetta P: Occupational exposure to ethylene oxide and risk of lymphoma. Epidemiology; 2010 Nov;21(6):905-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to ethylene oxide and risk of lymphoma.
  • BACKGROUND: Ethylene oxide, a high-volume commodity, is an established human carcinogen, although the relevant epidemiologic evidence is limited.
  • METHODS: We explored the association between occupational exposure to ethylene oxide and risk of lymphoma in a case-control study, including 2347 lymphoma cases first diagnosed in 1998-2004 and 2463 controls, from 6 European countries.
  • The diagnosis of lymphoma was based on the 2001 World Health Organization Classification of lymphoma.
  • We modeled risk of lymphoma with unconditional logistic regression analysis as a function of various exposure measures, adjusting for age, sex, and participating center.
  • Lymphoma risk showed a 4.3-fold increase associated with medium-high frequency of exposure to ethylene oxide (95% CI = 1.4-13).
  • Among major subtypes, chronic lymphocytic leukemia was consistently associated with ethylene oxide exposure, related in a dose-response manner to probability, frequency, and duration of exposure, as well as to cumulative exposure and (less definitively) with exposure intensity.
  • [MeSH-major] Carcinogens / toxicity. Ethylene Oxide / toxicity. Lymphoma / chemically induced. Occupational Exposure

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYLENE OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811284.001).
  • [ISSN] 1531-5487
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; JJH7GNN18P / Ethylene Oxide
  •  go-up   go-down


52. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J: The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol; 2010 Jan 1;84(1):1-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MicroRNAs are small non-coding RNAs that act at the post-transcriptional level, regulating protein expression by repressing translation or destabilizing mRNA target.
  • Because of their discovery, microRNAs have been associated with almost every normal cell function, including proliferation, differentiation and apoptosis.
  • Several lines of evidence suggest that they have an important role in normal hematopoiesis as exemplified by the role of mir-155 and mir-150 in the differentiation of B and T lymphocytes, the suppressive role of mir-221 and mir-222 in erythroid differentiation, the inhibitory effect of mir-181 on hematopoietic differentiation and the induction of myeloid differentiation by mir-223.
  • Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2.
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / genetics. Down-Regulation. Erythroid Precursor Cells / cytology. Gene Expression Regulation, Neoplastic / genetics. Genes, Tumor Suppressor. Humans. Invertebrates / genetics. Lymphocytes / cytology. Mice. Myeloid Cells / cytology. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Oncogenes. RNA, Neoplasm / antagonists & inhibitors. RNA, Neoplasm / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744129.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm
  • [Number-of-references] 110
  •  go-up   go-down


53. Bogner C, Sandherr M, Perker M, Weick K, Ringshausen I, Peschel C, Decker T: Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells. Ann Hematol; 2006 Jul;85(7):458-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells.
  • The clinical course of chronic lymphocytic leukemia is variable.
  • While some patients have indolent disease, others require aggressive treatment within a short time after diagnosis.
  • Differences in the expression of proteins regulating cell cycle and apoptosis may be responsible for the heterogeneous course of the disease.
  • Recently, protein ZAP 70 [zeta-chain (T-cell receptor) associated protein kinase 70 kDa] has been found to be differentially expressed within two biologic subgroups, characterized by the presence or absence of somatic mutations in specific immunoglobulin heavy-chain variable region genes.
  • In the present work, we analyzed highly purified B-CLL cells from 60 patients for ZAP 70 expression and the expression of cyclin E, bcl-2, bax, and mcl-1 as well as the ratios of bcl-2/bax and mcl-1/bax.
  • We conclude that higher cyclin E expression in samples of ZAP 70-positive patients may reflect a larger proliferating compartment in vivo compared to ZAP 70-negative patients and that cyclin E may add prognostic information in this context for patients with B-CLL.
  • [MeSH-major] Cyclin E / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Neoplasm Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. ZAP-70 Protein-Tyrosine Kinase / metabolism. bcl-2-Associated X Protein / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Myeloid Cell Leukemia Sequence 1 Protein. Neoplasm Staging. Tumor Cells, Cultured

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538501.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cyclin E; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


54. Li HX, Yan FH, Lei L: [Effects of Porphyromonas gingivalis lipopolysaccharide on apoptotic genes in foam cells]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 May;45(5):274-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Macrophages from THP-1 monocytes and foam cells from macrophages by oxLDL inducement were treated with oxidized low density lipoprotein (oxLDL) or oxLDL+ Pg-LPS.
  • Cell apoptosis was detected by acridine orange-ethidium bromide (AO-EB) staining.
  • RESULTS: Pg-LPS enhanced cell apoptosis rate during and after foam cells formation [(5.47+/-0.93)% vs. (7.50+/-0.54)%].
  • PCR array demonstrated that it increased B-cell CLL-lymphoma 2 (BCL2) related protein A1 (BCL2A1) transcription during foam cells formation (>2 fold), and promoted BCL2 and BCL2A1 transcription after foam cells formation (>2 fold).
  • CONCLUSIONS: Pg-LPS affected apoptotic gene transcription during and after foam cells formation and enhanced cell apoptosis.
  • [MeSH-minor] Caspase 3 / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Gene Expression. Humans. Lipoproteins, LDL / pharmacology. Macrophages / physiology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654241.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL2-related protein A1; 0 / Lipopolysaccharides; 0 / Lipoproteins, LDL; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; 0 / oxidized low density lipoprotein; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


55. Burton BJ, Cunningham ET Jr, Cree IA, Pavesio CE: Eye involvement mimicking scleritis in a patient with chronic lymphocytic leukaemia. Br J Ophthalmol; 2005 Jun;89(6):775-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eye involvement mimicking scleritis in a patient with chronic lymphocytic leukaemia.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemic Infiltration / diagnosis. Sclera / pathology. Scleritis / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eye (Lond). 2003 Jan;17(1):27-30 [12579166.001]
  • [Cites] Arch Ophthalmol. 1961 Oct;66:490-508 [13860566.001]
  • [Cites] Surv Ophthalmol. 1983 Jan-Feb;27(4):211-32 [6342189.001]
  • [Cites] Br J Ophthalmol. 1968 Oct;52(10):781-5 [5686969.001]
  • (PMID = 15923522.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1772664
  •  go-up   go-down


56. Gao Y, Kristinsson SY, Goldin LR, Björkholm M, Caporaso NE, Landgren O: Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology; 2009 Jan;136(1):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association.
  • BACKGROUND & AIMS: Celiac disease (CD), a common digestive disease, is well known to be associated with excess non-Hodgkin lymphoma (NHL) risk.
  • However, there are only limited data on risk in the current era of serologic testing and human leukocytes antigen typing to screen for CD.
  • There is also no information on the role of family history of CD in relation to lymphoma risk.
  • METHODS: We identified 37,869 NHL, 8323 Hodgkin lymphoma (HL), and 13,842 chronic lymphocytic leukemia patients diagnosed in Sweden between 1965 and 2004, as well as 236,408 matched controls and 613,961 first-degree relatives.
  • RESULTS: Overall we found persons with a hospital discharge diagnosis of CD to have a 5.35-fold (95% CI, 3.56-8.06) increased NHL risk.
  • Risk of HL was borderline increased (OR=2.54, 95% CI, 0.99-6.56); however, there was no excess chronic lymphocytic leukemia risk.
  • Persons diagnosed with CD in 1975-1984, 1985-1994, and 1995-2004 had a 13.2-fold (95% CI, 3.63-48.0), 7.90-fold (95% CI, 3.38-18.5), and 3.84-fold (95% CI, 2.28-6.45) increased risk of NHL, respectively (P(trend)< .0001).
  • Future studies are needed to explore the roles of gluten intake, secondary intestinal inflammation, and susceptibility genes in relation to subsequent risk of developing lymphoma.
  • [MeSH-major] Celiac Disease / complications. Celiac Disease / genetics. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Male. Middle Aged. Risk


57. Crespo M, Villamor N, Giné E, Muntañola A, Colomer D, Marafioti T, Jones M, Camós M, Campo E, Montserrat E, Bosch F: ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):726-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
  • PURPOSE: The ZAP-70 gene is normally expressed in T and natural killer cells, where it is required for the T-cell receptor (TCR) signaling.
  • More recently, it has been described that ZAP-70 contributes to the B-cell development at early stages of B-cell differentiation in mice.
  • The purpose was to investigate the presence of ZAP-70 in normal pro/pre B cells and mature B cells and in tumoral cells from B-acute lymphoblastic leukemias (B-ALL).
  • Among tumoral cells, ZAP-70 was expressed in 56% of B-ALLs with pro/pre B-cell phenotype and in 4 of 6 Burkitt/ALL lymphomas.
  • CONCLUSIONS: Among normal B-cell subsets, ZAP-70 was found expressed in normal pro/pre B cells but not in a significant proportion of normal B cells with mature phenotype.
  • The lack of ZAP-70 expression in normal mature B cells suggests that its expression in mature-derived neoplasms with different cellular origin, such as Burkitt's lymphoma and chronic lymphocytic leukemia, might be due to an aberrant phenomenon.
  • [MeSH-major] B-Lymphocytes / metabolism. Burkitt Lymphoma / genetics. Gene Expression Regulation. Gene Expression Regulation, Leukemic. Hematopoietic Stem Cells / metabolism. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA Mutational Analysis. Humans. Middle Aged. Phenotype. Phosphorylation. Receptors, Antigen, T-Cell / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467082.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


58. Molica S, Digiesi G, Battaglia C, Cutrona G, Antenucci A, Molica M, Giannarelli D, Sperduti I, Gentile M, Morabito F, Ferrarini M: Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur J Haematol; 2010 Oct;85(4):314-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
  • We analyzed the correlation between well-established biological parameters of prognostic relevance in B-cell chronic lymphocytic leukemia (CLL) [i.e. mutational status of the immunoglobulin heavy chain variable region (IgVH), ZAP-70 and CD38 expression] and serum levels of B cell-activating factor (BAFF of the TNF family) by evaluating the impact of these variables on the time to first treatment (TFT) in a series of 169 previously untreated CLL patients in Binet stage A.
  • Higher levels of BAFF were more frequently associated with female gender (P=0.02), younger age (P=0.01), Rai stage 0 (P=0.002), higher platelet count (P=0.005), mutated IgVH disease (P=0.002), higher occurrence of normal cytogenetic profile or presence of 13q deletion (P=0.02), low ZAP-70- (P=0.003), and CD38-expression (P=0.02).
  • Maximally selected log-rank statistic plot identified a serum BAFF concentration of 0.313 ng/mL as the best cut-off (P<0.0001).
  • This threshold recognized two subsets of patients with different TFT (P<0.0001).
  • Because in multivariate analysis soluble BAFF [Hazard ratio (HR), 8.23; confidence Interval (CI) 95%,3.0-22.6, P<0.0001] and mutational status of IgVH (HR=2.60; CI 95% 1.10-6.14, P=0.03) maintained the discriminating power their combined effect on clinical outcome was assessed.
  • (1) low-risk (n=93), patients with concordant IgVH(mut) and higher soluble BAFF;.
  • (2) intermediate-risk (n=50), patients with IgVH(mut) and low BAFF levels or IgVH(unmut) and soluble higher BAFF;(3) high-risk (n=26), patients with concordant IgVH (unmut) and low soluble BAFF, the 2-yr TFTs were, respectively, 95%, 85%, and 41% (P<0.0001).
  • In conclusion, our results indicate that in early B-cell CLL, the biological profile including among other parameters soluble BAFF may provide a useful insight into the complex interrelationship of prognostic variables.
  • [MeSH-major] B-Cell Activating Factor / blood. Biomarkers, Tumor / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20546021.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell Activating Factor; 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


59. Caldas LA, Attias M, de Souza W: Dynamin inhibitor impairs Toxoplasma gondii invasion. FEMS Microbiol Lett; 2009 Nov;301(1):103-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that previous incubation of the host cells, but not the parasites, with Dynasore, a small molecule that inhibits dynamin GTPase activity, markedly reduced the penetration of T. gondii tachyzoites into LLC-MK2 cells.
  • In contrast, parasite adhesion to the host cell surface increased, as observed both by light and electron microscopy.
  • Intriguingly, the few parasites internalized by Dynasore-treated cells remained in vacuoles located at the periphery of the cell, in contrast to the perinuclear localization seen in the control.
  • [MeSH-minor] Animals. Cell Adhesion. Cell Line. Dose-Response Relationship, Drug. Host-Parasite Interactions. Humans. Hydrazones / administration & dosage. Macaca mulatta. Mice. Microscopy, Electron, Scanning. Microscopy, Electron, Transmission. Vacuoles / metabolism. Vacuoles / parasitology

  • MedlinePlus Health Information. consumer health - Toxoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817867.001).
  • [ISSN] 1574-6968
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazones; 0 / N'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide; EC 3.6.5.5 / Dynamins
  •  go-up   go-down


60. Guggisberg K, Jordan RC: Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jan;109(1):98-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature.
  • OBJECTIVE: Mantle cell lymphoma (MCL) is a rare B-cell neoplasm that has only recently been defined as a distinct entity.
  • Because of its rarity and histologic similarities to other small cell lymphomas, the microscopic diagnosis of MCL may be challenging.
  • This is particularly true within the oral cavity, where other lymphomas are more frequent.
  • Historical cases were reviewed, and available data regarding morphology, special stains, demographics, clinical presentation, radiographic findings, management, and outcome were extracted.
  • CONCLUSION: We conclude that MCL of the oral cavity is an uncommon diagnosis.
  • The microscopic diagnosis can be challenging, given its similar appearance to other small cell lymphomas, requiring a comprehensive immunohistochemical panel for the accurate diagnosis.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • [Cites] Clin Oncol (R Coll Radiol). 2004 May;16(3):186-92 [15191005.001]
  • [Cites] J Oral Pathol. 1987 Jan;16(1):8-12 [3104566.001]
  • [Cites] Blood. 1990 Oct 1;76(7):1387-91 [2207314.001]
  • [Cites] Blood. 1991 Jul 15;78(2):259-63 [2070063.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):802-111 [8478674.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):249-56 [7612490.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):257-62 [7612491.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):627-40 [8619427.001]
  • [Cites] Curr Top Pathol. 1996;90:125-46 [8791750.001]
  • [Cites] Ear Nose Throat J. 1997 Jan;76(1):35-6 [9018933.001]
  • [Cites] J Oral Pathol Med. 1997 Jul;26(6):283-9 [9234189.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):567-75 [9452276.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):153-7 [11957138.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1785-91 [11681422.001]
  • [Cites] Ann Hematol. 2004 Feb;83(2):71-7 [14669040.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):316-20 [12973287.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Nov;92(5):519-25 [11709688.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jun;34(4):391-5 [16053848.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):303-10 [15716836.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):77-81 [15621784.001]
  • [Cites] J Laryngol Otol. 1998 Oct;112(10):991-4 [10211231.001]
  • [Cites] Head Neck. 1999 May;21(3):247-54 [10208668.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):29-38 [16173960.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):637-40 [1530105.001]
  • [Cites] Cancer. 2008 Aug 15;113(4):791-8 [18615506.001]
  • [Cites] Blood. 2008 Jan 15;111(2):558-65 [17962512.001]
  • [Cites] Histopathology. 2006 Mar;48(4):353-62 [16487357.001]
  • [Cites] Tumori. 2005 Nov-Dec;91(6):456-62 [16457141.001]
  • (PMID = 19880332.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / T32 DE017249; United States / NIDCR NIH HHS / DE / T32 DE017249-04; United States / NIDCR NIH HHS / DE / T32 DE017249-05; United States / NIDCR NIH HHS / DE / DE017249-04; United States / NIDCR NIH HHS / DE / T32 DE019096-02; United States / NIDCR NIH HHS / DE / DE017249-01; United States / NCI NIH HHS / CA / R21 CA095231; United States / NIDCR NIH HHS / DE / DE019096-02; United States / NIDCR NIH HHS / DE / T32 DE017249-03; United States / NCI NIH HHS / CA / R33 CA095231; United States / NIDCR NIH HHS / DE / T32 DE019096; United States / NIDCR NIH HHS / DE / T32DE017249; United States / NIDCR NIH HHS / DE / DE019096-01; United States / NIDCR NIH HHS / DE / T32 DE017249-02; United States / NIDCR NIH HHS / DE / DE017249-02; United States / NIDCR NIH HHS / DE / T32 DE019096-01; United States / NIDCR NIH HHS / DE / DE017249-03; United States / NIDCR NIH HHS / DE / T32 DE017249-01; United States / NIDCR NIH HHS / DE / DE017249-05; United States / NIDCR NIH HHS / DE / T32DE019096; United States / NCI NIH HHS / CA / CA095231
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1
  • [Number-of-references] 29
  • [Other-IDs] NLM/ NIHMS156688; NLM/ PMC2818374
  •  go-up   go-down


61. Wei J, Zhou S, Bachem MG, Debatin KM, Beltinger C: Infiltration of blood outgrowth endothelial cells into tumor spheroids: role of matrix metalloproteinases and irradiation. Anticancer Res; 2007 May-Jun;27(3B):1415-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Infiltration of BOECs into spheroids made of tumor cells and fibroblasts was determined in the presence of low-dose EDTA, a potent inhibitor of MMPs.
  • RESULTS: Infiltration of BOECs into spheroids was blocked by low-dose EDTA.
  • Irradiation enhanced secretion of MMP-2 and, less so, of MMP-9 by tumor-stromal cells and tumor cells, and increased the amount of MMP-2 and -9 in subcutaneous LLC tumors.
  • [MeSH-major] Blood Cells / physiology. Cell Movement. Endothelial Cells / physiology. Matrix Metalloproteinase 2 / physiology. Matrix Metalloproteinase 9 / physiology. Spheroids, Cellular / physiology

  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595756.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 9G34HU7RV0 / Edetic Acid; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


62. Manolov I, Machulla HJ, Momekov G: Synthesis, physicochemical characterization and preliminary pharmacological in vitro evaluation of two novel cytotoxic benzophenone-linked 3,3-dimethyltriazenes. Pharmazie; 2006 Jun;61(6):511-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of the novel benzophenone-linked triazenes and of ten other 1-phenyl-3,3-dimethyl triazene derivatives as well as of the referent alkylating drug melphalan was assessed using the MTT-dye reduction assay.
  • A panel of human tumor cell lines was used: the chronic lymphoid leukemia SKW-3, the acute promyelocyte leukemia HL-60 and its multi-drug-resistant subline HL-60/Dox.
  • DNA-fragmentation analysis indicated that after 24 h treatment the novel benzophenone-linked triazenes induced programmed cell death in HL-60 cells.
  • [MeSH-minor] Cell Line. Chemistry, Physical. DNA Fragmentation / drug effects. DNA, Neoplasm / biosynthesis. HL-60 Cells. Humans. Models, Molecular. Physicochemical Phenomena. Structure-Activity Relationship. Tetrazolium Salts. Thiazoles

  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826969.001).
  • [ISSN] 0031-7144
  • [Journal-full-title] Die Pharmazie
  • [ISO-abbreviation] Pharmazie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzophenones; 0 / DNA, Neoplasm; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Triazenes; 298-93-1 / thiazolyl blue
  •  go-up   go-down


63. Rankin JS, Orozco RE, Rodgers TL, Alfery DD, Glower DD: "Adjustable" artificial chordal replacement for repair of mitral valve prolapse. Ann Thorac Surg; 2006 Apr;81(4):1526-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gore & Associates Inc, Flagstaff, AZ) artificial chordal replacement and Carpentier ring annuloplasty (Edwards Lifesciences LLC, Irvine, CA), without leaflet resection.
  • Only 1 of 52 patients (1.9%) experienced late failure, and this patient was re-repaired with artificial chords.
  • Thus, "adjustable" artificial chordal replacement facilitates uniform repair of mitral valve prolapse with a low late failure rate.

  • MedlinePlus Health Information. consumer health - Mitral Valve Prolapse.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564319.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


64. Suresh K, Rodriguez-Lecompte JC, Gauldie J, Foley R: Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells. Hematology; 2005 Jun;10(3):189-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells.
  • Chronic lymphocytic leukemia (CLL) results from the relentless accumulation of small mature, slowly dividing, monoclonal B-lymphocytes.
  • The clinical course is heterogeneous, some patients with aggressive form of the disease progressing rapidly with early death while others exhibit a more stable, possibly, non-progressing indolent type of the disease lasting many years.
  • Despite progress in modern treatment modalities, relapse invariably occurs and disease still remains incurable.
  • The clinical management of CLL is therefore challenging and considerable effort has been directed towards novel therapeutic strategies aimed at reducing minimal residual disease which can increase remission duration.
  • Ex-vivo modified and monocyte-derived DCs represents a promising approach within the context of CLL.
  • After a brief survey of general properties of DCs, this review focuses on the different approaches exploiting monocyte-derived DCs in CLL, which may help to design novel strategies for phase-I clinical trials.
  • [MeSH-major] Dendritic Cells / transplantation. Immunotherapy, Adoptive. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Monocytes / transplantation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019468.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 109
  •  go-up   go-down


65. Hwang HS, Min YS, Lee SC, Sun MK, Lim HS: Change of lip-line cant after 1-jaw orthognathic surgery in patients with mandibular asymmetry. Am J Orthod Dentofacial Orthop; 2009 Oct;136(4):564-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The purpose of this study was to investigate the change of lip-line cant (LLC) after 1-jaw orthognathic surgery in mandibular asymmetry patients.
  • LLC was measured in the preoperative and postoperative frontal photographs, and its change was correlated with various craniofacial measurements obtained from preoperative and postoperative frontal cephalograms and maxillofacial 3-dimensional computed tomography images.
  • RESULTS: Although these subjects had 2.4 degrees of LLC on average before surgery, LLC improved to 0.5 degrees after surgery, and the change (1.9 degrees ) was statistically significant.
  • In the correlation analysis, preoperative LLC showed positive correlations with menton deviation and mandibular anterior occlusal plane cant.
  • In the correlation analysis of LLC change, it had positive correlations with preoperative LLC and mandibular anterior occlusal plane cant and preoperative and postoperative change of menton deviation.
  • CONCLUSIONS: These results suggest that LLC is present with chin deviation, even without significant maxillary canting, and can be improved considerably by 1-jaw surgery alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815160.001).
  • [ISSN] 1097-6752
  • [Journal-full-title] American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics
  • [ISO-abbreviation] Am J Orthod Dentofacial Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Collins SA, Buhles A, Scallan MF, Harrison PT, O'Hanlon DM, O'Sullivan GC, Tangney M: AAV2-mediated in vivo immune gene therapy of solid tumours. Genet Vaccines Ther; 2010;8:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immune-competent Balb/C or C57 mice bearing subcutaneous JBS fibrosarcoma or Lewis Lung Carcinoma (LLC) tumour xenografts respectively were treated by intra-tumoural administration of AAV2 vector encoding the immune up-regulating cytokine granulocyte macrophage-colony stimulating factor (GM-CSF) and the co-stimulatory molecule B7-1 to subcutaneous tumours, either alone or in combination with intra-muscular (IM) delivery of AAV2 vector encoding Nk4 14 days prior to tumour induction.
  • Cured animals were re-challenged with tumourigenic doses of the original tumour type.
  • In vivo cytotoxicity assays were used to investigate establishment of cell-mediated responses in treated animals.
  • RESULTS: AAV2-mediated GM-CSF, B7-1 treatment resulted in a significant reduction in tumour growth and an increase in survival in both tumour models.
  • Cured animals were resistant to re-challenge, and induction of T cell mediated anti-tumour responses were demonstrated.
  • CONCLUSIONS: Overall, this study demonstrates the potential for in vivo AAV2 mediated immune gene therapy, and provides data on the inter-relationship between tumour vasculature and immune cell recruitment.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tissue Antigens. 2003 Mar;61(3):211-9 [12694570.001]
  • [Cites] Crit Rev Oncol Hematol. 1999 Feb;29(3):209-48 [10226727.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2442-50 [16489051.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):939-49 [18245558.001]
  • [Cites] Gene Ther. 2008 Jun;15(11):808-16 [18385765.001]
  • [Cites] Curr Gene Ther. 2008 Apr;8(2):66-78 [18393828.001]
  • [Cites] Genet Vaccines Ther. 2009;7:5 [19272140.001]
  • [Cites] Neuromolecular Med. 2009;11(1):43-52 [19306089.001]
  • [Cites] J Cell Biol. 1996 May;133(3):709-18 [8636243.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):13110-5 [8662798.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Oct 29;239(3):639-44 [9367820.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1181-94 [11002212.001]
  • [Cites] Clin Experiment Ophthalmol. 2000 Oct;28(5):382-6 [11097287.001]
  • [Cites] Cell. 1992 Dec 24;71(7):1093-102 [1335364.001]
  • [Cites] Cancer Gene Ther. 2006 Dec;13(12):1061-71 [16874363.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):5031-5 [2164219.001]
  • [Cites] Nat Immun Cell Growth Regul. 1990;9(3):165-72 [2370876.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2560-6 [2580624.001]
  • [Cites] CA Cancer J Clin. 1972 Jul-Aug;22(4):226-9 [4625047.001]
  • [Cites] J Exp Med. 1983 Mar 1;157(3):1040-52 [6187879.001]
  • [Cites] Nature. 1984 Oct 25-31;311(5988):750-2 [6333639.001]
  • [Cites] J Immunol. 1993 Apr 15;150(8 Pt 1):3161-9 [7682233.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):1-6 [9450538.001]
  • [Cites] Cell Growth Differ. 1998 May;9(5):355-65 [9607557.001]
  • [Cites] Nat Med. 1999 Jan;5(1):56-63 [9883840.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1204-11 [11466335.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):719-25 [11857345.001]
  • [Cites] Cancer Sci. 2003 Apr;94(4):321-7 [12824898.001]
  • [Cites] Ernst Schering Res Found Workshop. 2003;(43):107-14 [12894454.001]
  • [Cites] Int J Cardiol. 2003 Aug;90(2-3):229-38 [12957756.001]
  • [Cites] J Immunol. 1961 Feb;86:228-39 [13785862.001]
  • [Cites] Dis Esophagus. 2003;16(3):218-23 [14641313.001]
  • [Cites] Gene Ther. 2004 Mar;11(6):534-43 [14999225.001]
  • [Cites] Eur J Immunol. 2004 Oct;34(10):2635-41 [15368278.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):316-27 [15950947.001]
  • [Cites] Cancer Gene Ther. 2005 Dec;12(12):913-25 [15962012.001]
  • [Cites] Gene Ther. 2005 Oct;12 Suppl 1:S159-69 [16231050.001]
  • [Cites] Cancer Immunol Immunother. 2006 Nov;55(11):1443-50 [16612593.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):523-32 [7507508.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1205-14 [7511683.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6477-83 [7527298.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1857-65 [7583565.001]
  • [Cites] Cancer Gene Ther. 1996 May-Jun;3(3):202-14 [8725885.001]
  • [Cites] Gene Ther. 1997 Mar;4(3):181-8 [9135731.001]
  • [Cites] Ciba Found Symp. 1997;212:119-30; discussion 130-2, 148-54 [9524767.001]
  • [Cites] Nat Med. 1998 May;4(5 Suppl):525-31 [9585204.001]
  • [Cites] Hum Gene Ther. 1999 Jan 20;10(2):201-13 [10022545.001]
  • [Cites] Nat Biotechnol. 1999 Feb;17(2):181-6 [10052356.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3906-10 [10097136.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):257-61 [10700178.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1317-26 [10942373.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 29;279(3):846-52 [11162438.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):604-8 [11406663.001]
  • [Cites] Hum Gene Ther. 2001 Oct 10;12(15):1907-16 [11589832.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):185-93 [11900993.001]
  • [Cites] J Virol. 2002 Dec;76(24):12900-7 [12438615.001]
  • [Cites] Nat Med. 2008 Jan;14(1):28-36 [18157142.001]
  • [Cites] Nature. 2008 May 15;453(7193):410-4 [18418378.001]
  • [Cites] Ultrasound Med Biol. 2010 Mar;36(3):430-40 [20133039.001]
  • [Cites] Cancer Gene Ther. 2010 Jul;17(7):501-11 [20186173.001]
  • [Cites] Postgrad Med. 2010 May;122(3):166-80 [20463426.001]
  • [Cites] Gene Ther. 2010 Aug;17(8):1042-51 [20596059.001]
  • [Cites] Trends Cell Biol. 1998 Oct;8(10):404-10 [9789329.001]
  • [Cites] Kidney Int. 2004 Aug;66(2):586-90 [15253710.001]
  • (PMID = 21172020.001).
  • [ISSN] 1479-0556
  • [Journal-full-title] Genetic vaccines and therapy
  • [ISO-abbreviation] Genet Vaccines Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3016353
  •  go-up   go-down


67. Küçköztaş MF, Ozgünes N, Yazici S: [Investigation of the relationship between hepatitis c virus (HCV) genotypes with HCV-RNA and alanine aminotransferase levels in chronic hepatitis c patients]. Mikrobiyol Bul; 2010 Jan;44(1):111-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation of the relationship between hepatitis c virus (HCV) genotypes with HCV-RNA and alanine aminotransferase levels in chronic hepatitis c patients].
  • The objective of this retrospective study was to determine the distribution of HCV genotypes in patients with chronic hepatitis C infection at our region and to investigate the relation between genotypes and serum alanine aminotransferase (ALT) and HCV-RNA levels.
  • Serum samples from 52 patients (26 females, 26 males; mean age: 51.07 +/- 13.13 years) with chronic HCV infection were analyzed in this study.
  • Viral genotypes were determined by using the Versant HCV genotype assay (LiPA) 2.0 system (Bayer HealthCare LLC, USA) according to the manufacturer's instructions.
  • The mean age of the patients infected with genotype 1 (51.4 +/- 12.6 years) we e statistically significantly higher than the mean age of the patients infected with type 2 and 3 (37.8 +/- 12.3 years), (p = 0.023).
  • [MeSH-major] Alanine Transaminase / blood. Hepacivirus / genetics. Hepatitis C, Chronic / enzymology. Hepatitis C, Chronic / virology. RNA, Viral / blood

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20455406.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / RNA, Viral; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


68. Kano R, Sato E, Okamura T, Watanabe S, Hasegawa A: Expression of Bcl-2 in feline lymphoma cell lines. Vet Clin Pathol; 2008 Mar;37(1):57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Bcl-2 in feline lymphoma cell lines.
  • Bcl-2 has been shown to repress cell death triggered by a diverse array of stimuli, including chemotherapy and gamma irradiation.
  • OBJECTIVE: The purpose of this study was to determine feline Bcl-2 expression level in feline lymphoma cells using an immunoblot assay with anti-human and anti-canine Bcl-2 monoclonal antibodies.
  • An immunoblot assay using the monoclonal antibodies was carried out to determine the level of feline Bcl-2 expression in lymphoma and lymphocytic leukemia cell lines.
  • RESULTS: The recombinant feline Bcl-2 protein produced in E. coli had a molecular weight of about 26 kDa and was detected by immunoblot assay by using anti-human Bcl-2 mouse monoclonal antibody.
  • Feline Bcl-2 expression was high in lymphoma cell lines (FL-74-UDC-1 and FT-1) and low in the cell line from peripheral blood mononuclear cells from a healthy cat (FeTJ-1) but not low in freshly isolated peripheral blood mononuclear cells from a healthy cat.
  • CONCLUSIONS: These results confirm the expression of Bcl-2 in T-cell lymphoma cell lines and indicate that it is suitable to detect feline Bcl-2 using an immunoblot assay.
  • Pending further evaluation, Bcl-2 expression might be useful in the differential diagnosis of feline tumors.


69. Edwards TB, Gartsman GM, O'Connor DP, Sarin VK: Safety and utility of computer-aided shoulder arthroplasty. J Shoulder Elbow Surg; 2008 May-Jun;17(3):503-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study evaluated the safety and utility of a novel, image-free, shoulder navigation system in a cadaver and in an initial cohort of shoulder arthroplasty patients.
  • Shoulder arthroplasty was performed on a cadaver and 27 patients using an image-free navigation system (NaviProtrade mark; Kinamed Navigation Systems LLC, Camarillo, CA).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262802.001).
  • [ISSN] 1532-6500
  • [Journal-full-title] Journal of shoulder and elbow surgery
  • [ISO-abbreviation] J Shoulder Elbow Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Yang C, Kaushal V, Shah SV, Kaushal GP: Mcl-1 is downregulated in cisplatin-induced apoptosis, and proteasome inhibitors restore Mcl-1 and promote survival in renal tubular epithelial cells. Am J Physiol Renal Physiol; 2007 Jun;292(6):F1710-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mcl-1 is an antiapoptotic member of the Bcl-2 family that plays an important role in cell survival.
  • We demonstrate that proteasome-dependent regulation of Mcl-1 plays a critical role in renal tubular epithelial cell injury from cisplatin.
  • Protein levels of Mcl-1 rapidly declined in a time-dependent manner following cisplatin treatment of LLC-PK(1) cells.
  • [MeSH-minor] Animals. Caspase 3 / metabolism. Cell Survival / drug effects. Fluorescent Antibody Technique. LLC-PK1 Cells. Myeloid Cell Leukemia Sequence 1 Protein. Reverse Transcriptase Polymerase Chain Reaction. Swine

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17311906.001).
  • [ISSN] 1931-857X
  • [Journal-full-title] American journal of physiology. Renal physiology
  • [ISO-abbreviation] Am. J. Physiol. Renal Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proteasome Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.22.- / Caspase 3; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


71. Saygili EI, Aksoy N, Pehlivan M, Sever T, Yilmaz M, Cimenci IG, Pehlivan S: Enzyme levels and G-463A polymorphism of myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma. Leuk Lymphoma; 2009 Dec;50(12):2030-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enzyme levels and G-463A polymorphism of myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma.
  • The aim of this study was to investigate how myeloperoxidase (MPO) G-463A gene polymorphism and enzyme levels varied among patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) and to find the relationship between the MPO gene, enzyme levels, and clinical parameters.
  • We studied the sera from 40 healthy volunteers, patients with CLL (n = 34) and MM (n = 28).
  • In subjects with homozygote GG genotype, MPO levels were higher in the patients with both CLL and MM than in the control group.
  • This difference was statistically significant in patients with CLL.
  • In accordance with the results of the study, we assess that the increase in the MPO enzyme level in the patient groups with CLL and MM generated bactericidal effects as well as the increased formation of ROP, thus setting off a pro-cell death pathway and playing a role on the pathogenesis of lymphoproliferative malignancies through this mechanism.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Multiple Myeloma / genetics. Peroxidase / genetics


72. Kojima M, Sato E, Oshimi K, Murase T, Koike T, Tsunoda S, Matsumoto T, Marutsuka K, Ogiya D, Moriuchi M, Tokunaka M, Yara Kikuti Y, Kikuchi T, Nakamura N, Ando K: Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation ; clinical, flow cytometry, and histopathological findings of 11 cases. J Clin Exp Hematop; 2010;50(2):107-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation ; clinical, flow cytometry, and histopathological findings of 11 cases.
  • Splenic marginal zone lymphoma (SP-MZL) is a rare low-grade B-cell neoplasm that often shows leukemic manifestation.
  • The clinical characteristics of these cases did not differ from those of CD5-negative SP-MZL.
  • Flow cytometry revealed positive results as follows : CD3, 0/9 ; CD5, 11/11 ; CD10, 0/11 ; CD11c, 4/10, CD13, 5/11 ; CD19, 11/11 ; CD20, 10/11 ; CD21, 4/4 ; CD22, 7/7 ; CD23, 5/10 ; CD25, 8/11 ; FMC7, 5/7 ; κ type 6/9, and λ type 2/9.
  • Immunohistochemistry showed that the lymphoma cells were positive for CD5, CD20, and BCL-2 and negative for CD3, CD10, cyclin D1, BCL-6, and MUM-1 in all 11 cases.
  • These results suggest that CD5-positive SP-MZL differs from B-cell chronic lymphocytic leukemia, that CD13 expression is found in about half of CD5-positive SP-MZL cases, and that CD5-positive SP-MZL may be related to memory B-cell neoplasm or plasma cell differentiation.
  • [MeSH-major] Antigens, CD5 / metabolism. Lymphoma, B-Cell, Marginal Zone / metabolism. Lymphoma, B-Cell, Marginal Zone / pathology. Splenic Neoplasms / metabolism. Splenic Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21123968.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Biomarkers, Tumor
  •  go-up   go-down


73. Kreitman RJ, Pastan I: Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets; 2006 Oct;7(10):1301-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunotoxins, composed of protein toxins connected to cell binding ligands including monoclonal antibodies and growth factors, have been developed for several decades to target hematologic malignancies.
  • Plant toxins, particularly ricin, are useful for chemically conjugating to monoclonal antibodies, and have shown clinical activity in several types of lymphoma and leukemia.
  • Their dose is generally limited by vascular leak syndrome.
  • Denileukin diftitox has shown efficacy in cutaneous T-cell lymphoma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma.
  • Recombinant immunotoxin BL22 is an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin; it induces complete remissions in a high percentage of patients with chemoresistant hairy cell leukemia.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17073592.001).
  • [ISSN] 1873-5592
  • [Journal-full-title] Current drug targets
  • [ISO-abbreviation] Curr Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunotoxins
  • [Number-of-references] 235
  •  go-up   go-down


74. Marina O, Hainz U, Biernacki MA, Zhang W, Cai A, Duke-Cohan JS, Liu F, Brusic V, Neuberg D, Kutok JL, Alyea EP, Canning CM, Soiffer RJ, Ritz J, Wu CJ: Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res; 2010 Feb 15;70(4):1344-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.
  • Patients with chronic lymphocytic leukemia (CLL) who relapse after allogeneic transplant may achieve durable remission following donor lymphocyte infusion (DLI), showing the potency of donor-derived immunity in eradicating tumors.
  • We sought to elucidate the antigenic basis of the effective graft-versus-leukemia (GvL) responses associated with DLI for the treatment of CLL by analyzing the specificity of plasma antibody responses developing in two DLI-treated patients who achieved long-term remission without graft-versus-host disease.
  • Along with additional candidate antigens DAPK3, SERBP1, and OGFOD1, these proteins showed higher transcript and protein expression in B cells and CLL cells compared with normal peripheral blood mononuclear cells.
  • Although ZFYVE19, DAPK3, and OGFOD1 elicited minimal antibody reactivity in 12 normal subjects and 12 chemotherapy-treated CLL patients, 5 of 12 CLL patients with clinical GvL responses were serologically reactive to these antigens.
  • Moreover, antibody reactivity against these antigens was temporally correlated with clinical disease regression.
  • These B-cell antigens represent promising biomarkers of effective anti-CLL immunity.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2005 Nov;36(9):825-30 [16151430.001]
  • [Cites] Genome Biol. 2001;2(11):SOFTWARE0002 [16173164.001]
  • [Cites] Exp Hematol. 2006 Jan;34(1):44-53 [16413390.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1724-30 [16239425.001]
  • [Cites] Methods Enzymol. 2005;403:1-10 [16473572.001]
  • [Cites] Cancer Biol Ther. 2006 Feb;5(2):145-9 [16357522.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):210-9 [16616068.001]
  • [Cites] Adv Immunol. 2006;90:133-73 [16730263.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2028-36 [17071473.001]
  • [Cites] Leukemia. 2007 Jan;21(1):12-7 [17109028.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D680-4 [17132831.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1355-62 [17008540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52 [17517626.001]
  • [Cites] Proteomics. 2007 Mar;7(6):976-91 [17370257.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):557-68 [17707840.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):266-73 [17698176.001]
  • [Cites] Science. 2008 Jan 11;319(5860):215-20 [18187659.001]
  • [Cites] J Proteome Res. 2008 May;7(5):2059-68 [18393456.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4759-68 [19567591.001]
  • [Cites] Nat Med. 2000 Jun;6(6):667-72 [10835683.001]
  • [Cites] J Clin Invest. 2000 Sep;106(5):705-14 [10974024.001]
  • [Cites] Leukemia. 2001 Mar;15(3):445-51 [11237069.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2101-5 [11474067.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2123-31 [12200376.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1400-10 [12618766.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1656-65 [12738718.001]
  • [Cites] EMBO J. 2003 Jul 15;22(14):3664-74 [12853481.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2747-53 [12860954.001]
  • [Cites] Bioinformatics. 2004 Aug 12;20(12):1962-3 [14988114.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3937-49 [15459216.001]
  • [Cites] Genome Res. 2004 Oct;14(10B):2128-35 [15489335.001]
  • [Cites] Genomics. 1996 Apr 1;33(1):151-2 [8617505.001]
  • [Cites] Bone Marrow Transplant. 1996 Sep;18(3):669-72 [8879640.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):433-44 [9053463.001]
  • [Cites] J Exp Med. 1998 Jan 19;187(2):265-70 [9432985.001]
  • [Cites] Immunol Res. 1997;16(4):313-39 [9439758.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1642-51 [9488481.001]
  • [Cites] Blood. 1998 May 15;91(10):3671-80 [9573003.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):371-80 [9892619.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2973-8 [15613541.001]
  • [Cites] Blood. 2005 May 15;105(10):3945-50 [15692072.001]
  • [Cites] Int J Androl. 2005 Jun;28(3):163-70 [15910542.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5788-94 [16043827.001]
  • [Cites] J Biol Chem. 2005 Aug 26;280(34):30564-73 [15985431.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4389-96 [16131571.001]
  • (PMID = 20124481.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5R21CA115043-2; United States / NCI NIH HHS / CA / R21 CA132232-02; United States / NCI NIH HHS / CA / P01 CA078378; United States / NCI NIH HHS / CA / P01 CA155258; United States / NCI NIH HHS / CA / CA132232-02; United States / NCI NIH HHS / CA / R21 CA132232; United States / NCI NIH HHS / CA / R21 CA115043; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / P50 CA100707
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; 0 / Immunodominant Epitopes
  • [Other-IDs] NLM/ NIHMS167268; NLM/ PMC2852266
  •  go-up   go-down


75. Kokhaei P, Palma M, Mellstedt H, Choudhury A: Biology and treatment of chronic lymphocytic leukemia. Ann Oncol; 2005;16 Suppl 2:ii113-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology and treatment of chronic lymphocytic leukemia.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958440.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Genetic Markers
  • [Number-of-references] 90
  •  go-up   go-down


76. Majumder D, Banerjee D, Chandra S, Banerjee S, Chakrabarti A: Red cell morphology in leukemia, hypoplastic anemia and myelodysplastic syndrome. Pathophysiology; 2006 Dec;13(4):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Red cell morphology in leukemia, hypoplastic anemia and myelodysplastic syndrome.
  • In the present work, we have studied the overall morphology of intact red cells in different leukemic patients along with patients of hypoplastic anemia (HPA) by scanning electron microscopy.
  • We have also studied the ultrastructure of the red cell surface membranes by transmission electron microscopy.
  • We have shown direct evidence of the altered red cell (RBC) membrane morphology irrespective of the hemoglobin status of the patients which includes (1) presence of large central holes in RBCs of acute myeloid leukemia (AML), (2) presence of thorn- and horn-like structure in RBCs of acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) and (3) flaccid appearance of RBCs in chronic lymphocytic leukemia (CLL) patients.
  • TEM studies revealed presence of pores with diameters ranging from 100 to 200nm on the RBC membrane surface of myeloid leukemia with AML being the most prominent among others.
  • Such pathophysiological alterations of the RBC morphology in leukemic patients could be identified as characteristic signature of the onset of anemia associated with the disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876391.001).
  • [ISSN] 0928-4680
  • [Journal-full-title] Pathophysiology : the official journal of the International Society for Pathophysiology
  • [ISO-abbreviation] Pathophysiology
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


77. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P: Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood; 2008 Sep 1;112(5):1912-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
  • Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, and resistance to fludarabine-based therapies is a major challenge in CLL treatment.
  • Because CLL cells are known to have elevated levels of reactive oxygen species (ROS), we aimed to test a novel ROS-mediated strategy to eliminate fludarabine-resistant CLL cells based on this redox alteration.
  • Using primary CLL cells and normal lymphocytes from patients (n = 58) and healthy subjects (n = 12), we showed that both fludarabine-resistant and -sensitive CLL cells were highly sensitive to beta-phenylethyl isothiocyanate (PEITC) with mean IC(50) values of 5.4 microM and 5.1 microM, respectively.
  • Normal lymphocytes were significantly less sensitive to PEITC (IC(50) = 27 microM, P < .001).
  • CLL cells exhibited intrinsically higher ROS level and lower cellular glutathione, which were shown to be the critical determinants of CLL sensitivity to PEITC.
  • Exposure of CLL cells to PEITC induced severe glutathione depletion, ROS accumulation, and oxidation of mitochondrial cardiolipin leading to massive cell death.
  • Such ROS stress also caused deglutathionylation of MCL1, followed by a rapid degradation of this cell survival molecule.
  • Our study demonstrated that the natural compound PEITC is effective in eliminating fludarabine-resistant CLL cells through a redox-mediated mechanism with low toxicity to normal lymphocytes, and warrants further clinical evaluation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Jun 17;23(28):4818-27 [15122313.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:153-75 [14633781.001]
  • [Cites] Am J Hematol. 2004 Jan;75(1):22-33 [14695629.001]
  • [Cites] Drug Resist Updat. 2003 Dec;6(6):323-8 [14744496.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Mar;53(3):209-19 [14610616.001]
  • [Cites] Arch Biochem Biophys. 2004 Mar 1;423(1):37-46 [14989263.001]
  • [Cites] Drug Resist Updat. 2004 Apr;7(2):97-110 [15158766.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):499-512 [17707836.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8653-61 [17875705.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):32233-42 [17823113.001]
  • [Cites] Am J Hematol. 1988 Nov;29(3):152-63 [3189311.001]
  • [Cites] Br J Haematol. 1989 May;72(1):32-5 [2786733.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]
  • [Cites] Blood. 1993 Jan 1;81(1):143-50 [8093345.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jan 17;206(2):748-55 [7826396.001]
  • [Cites] Jpn J Pharmacol. 1996 Aug;71(4):299-305 [8886927.001]
  • [Cites] Blood. 1998 May 1;91(9):3379-89 [9558396.001]
  • [Cites] Semin Liver Dis. 1998;18(4):389-401 [9875556.001]
  • [Cites] Free Radic Biol Med. 2004 Dec 1;37(11):1821-33 [15528041.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1934-40 [15483672.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):640-5 [15577914.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4738-44 [15550399.001]
  • [Cites] Biochemistry. 2005 Apr 19;44(15):5899-906 [15823049.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4820-7 [15728130.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):123-7 [16001073.001]
  • [Cites] Free Radic Res. 2005 Jun;39(6):573-80 [16036334.001]
  • [Cites] EMBO J. 2005 Oct 5;24(19):3482-92 [16163384.001]
  • [Cites] Braz J Med Biol Res. 2006 Mar;39(3):327-33 [16501812.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):437-45 [16272172.001]
  • [Cites] Crit Rev Clin Lab Sci. 2006;43(2):143-81 [16517421.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):210-9 [16616068.001]
  • [Cites] Science. 2006 Jun 16;312(5780):1650-3 [16728594.001]
  • [Cites] Expert Opin Pharmacother. 2006 Aug;7(12):1641-51 [16872267.001]
  • [Cites] Cancer Cell. 2006 Sep;10(3):241-52 [16959615.001]
  • [Cites] Leuk Lymphoma. 2007 Feb;48(2):311-20 [17325891.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2144-50 [17404098.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6217-22 [17389404.001]
  • [Cites] Biochemistry. 2007 Jul 3;46(26):7765-80 [17555331.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6409-16 [17616701.001]
  • [Cites] Clin Chim Acta. 2000 Mar;293(1-2):53-62 [10699422.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1405-13 [10942236.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):183-93 [10998361.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 1;30(11):1286-92 [11368926.001]
  • [Cites] Anal Biochem. 2001 Apr 15;291(2):279-89 [11401302.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1795-801 [12176902.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):43730-4 [12223490.001]
  • [Cites] Blood. 2003 May 15;101(10):4098-104 [12531810.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37832-9 [12853461.001]
  • [Cites] Cell Death Differ. 2004 Jul;11 Suppl 1:S73-85 [15105835.001]
  • (PMID = 18574029.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100428; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA085563; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA109041; United States / NCI NIH HHS / CA / R01 CA109041; United States / NCI NIH HHS / CA / CA100428; United States / NCI NIH HHS / CA / CA085563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Isothiocyanates; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Reactive Oxygen Species; 6U7TFK75KV / phenethyl isothiocyanate; 9007-43-6 / Cytochromes c; EC 1.11.1.9 / Glutathione Peroxidase; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; FA2DM6879K / Vidarabine; GAN16C9B8O / Glutathione; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2518893
  •  go-up   go-down


78. Reuters I, Weber M, Schulze-Lohoff E: Rho/Rho kinase pathway regulates maintenance of the differentiated tubular epithelial cell phenotype on laminin-1. Nephron Physiol; 2006;104(2):p95-p106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rho/Rho kinase pathway regulates maintenance of the differentiated tubular epithelial cell phenotype on laminin-1.
  • BACKGROUND: Maintenance of a polarized tubular epithelium by appropriate intracellular signaling and extracellular matrix is critical both in normal renal function as well as in acute and chronic tubular injury.
  • We examined the hypothesis that maintenance of a differentiated epithelial phenotype on the basement membrane glycoprotein laminin-1 is controlled by the Rho/Rho kinase pathway.
  • METHODS: Using the tubular epithelial cell lines LLC-PK1 and MDCK which were cultured on laminin-1 vs. collagen IV, we analyzed cell morphology and motility (cohort migration assay) as well as expression of differentiation and dedifferentiation markers (immunofluorescence microscopy).
  • RESULTS: Cohort migration of LLC-PK1 cells was significantly slowed down on laminin-1 (10.7 +/- 2.2 m.u. (migratory units)) compared with collagen IV (16.6 +/- 2.3 m.u.
  • In parallel to the increased migratory activity, inhibition of the Rho/Rho kinase pathway resulted in a more mesenchymal phenotype of LLC-PK1 cells on laminin-1 with increased formation of lamellopodia and filopodia, distinct loss of focal contacts and stress fibers, upregulation of the dedifferentiation marker vimentin, and loss of cell-cell contacts with translocation of beta-catenin from the adherens junctions to the cytosol and nucleus.
  • Similarly, cohort migration of MDCK cells was retarded on laminin-1 when compared with collagen IV, and addition of the Rho kinase inhibitor Y27632 resulted in enhanced motility and a change in cell morphology.
  • CONCLUSION: The study demonstrates that the Rho/Rho kinase pathway is required to maintain a non-migratory epithelial phenotype of cultured renal tubular LLC-PK1 and MDCK cells on the basement membrane glycoprotein laminin-1.
  • [MeSH-minor] Animals. Cell Differentiation. Cell Line. Cell Movement. Dogs. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Phenotype. Signal Transduction / drug effects. Signal Transduction / physiology. Swine. rho-Associated Kinases

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16847378.001).
  • [ISSN] 1660-2137
  • [Journal-full-title] Nephron. Physiology
  • [ISO-abbreviation] Nephron Physiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Laminin; 0 / laminin 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / rho-Associated Kinases; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


79. Virgin F, Zhang S, Schuster D, Azbell C, Fortenberry J, Sorscher EJ, Woodworth BA: The bioflavonoid compound, sinupret, stimulates transepithelial chloride transport in vitro and in vivo. Laryngoscope; 2010 May;120(5):1051-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Dehydration of airway surface liquid (ASL) disrupts normal mucociliary clearance in sinonasal epithelium leading to chronic rhinosinusitis.
  • Abnormal chloride (Cl(-)) transport is one mechanism that contributes to this disorder, as demonstrated by the disease cystic fibrosis.
  • Sinupret (Bionorica, LLC, San Clemente, CA), a combination of naturally occurring bioflavonoids, is a widely used treatment for respiratory ailments in Europe.
  • METHODS: Well characterized murine nasal septal epithelial (MNSE) cultures, and murine nasal potential difference (NPD) techniques were used to evaluate the effects of Sinupret on Cl(-) secretion.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422703.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chloride Channels; 0 / Chlorides; 0 / Flavonoids; 0 / Plant Extracts; 1F7A44V6OU / Colforsin; 77321-52-9 / Sinupret
  •  go-up   go-down


80. Biebinger R, Zimmermann MB, Al-Hooti SN, Al-Hamed N, Al-Salem E, Zafar T, Kabir Y, Al-Obaid I, Petry N, Hurrell RF: Efficacy of wheat-based biscuits fortified with microcapsules containing ferrous sulfate and potassium iodate or a new hydrogen-reduced elemental iron: a randomised, double-blind, controlled trial in Kuwaiti women. Br J Nutr; 2009 Nov;102(9):1362-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first objective of the study was to measure the efficacy in wheat flour of two newly developed Fe compounds, an H-reduced Fe powder (NutraFine RS; North America Höganäs High Alloys LLC, Johnstown, PA, USA) and small particle-sized (40 microm) encapsulated FeSO4.
  • A randomised, double-blind controlled intervention trial was conducted in Kuwaiti women (n 279; aged 18-35 years) with low body Fe stores (serum ferritin (SF) < 25 microg/l) randomly assigned to one of three groups (20 mg Fe as NutraFine RS, 10 mg Fe as encapsulated FeSO4 and 150 microg iodine, or no fortification Fe) who consumed wheat-based biscuits 5 d per week.
  • Relative to control, mean SF in the encapsulated FeSO4 group increased by 88 % (P < 0.001) and body Fe stores increased from - 0.96 to 2.24 mg/kg body weight (P < 0.001), while NutraFine RS did not significantly increase SF or body Fe stores.
  • The median urinary iodine concentration increased from 140 to 213 microg/l (P < 0.01).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. FERROUS SULFATE .
  • Hazardous Substances Data Bank. POTASSIUM IODATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653920.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Capsules; 0 / Ferrous Compounds; 0 / Hemoglobins; 0 / Iodates; 0 / Iron, Dietary; 0 / Potassium Compounds; 0 / Transferrin; 39R4TAN1VT / ferrous sulfate; E1UOL152H7 / Iron; I139E44NHL / potassium iodate
  •  go-up   go-down


81. Chen Z, Wang Y, Ratia K, Mesecar AD, Wilkinson KD, Baker SC: Proteolytic processing and deubiquitinating activity of papain-like proteases of human coronavirus NL63. J Virol; 2007 Jun;81(11):6007-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human coronavirus NL63 (HCoV-NL63), a common human respiratory pathogen, is associated with both upper and lower respiratory tract disease in children and adults.
  • We generated polyclonal antisera directed against two of the predicted replicase nonstructural proteins (nsp3 and nsp4) and detected replicase proteins from HCoV-NL63-infected LLC-MK2 cells by immunofluorescence, immunoprecipitation, and Western blot assays.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2004 Jun;78(11):5957-65 [15140993.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7 [15226499.001]
  • [Cites] Nucleic Acids Res. 2004;32(14):e115 [15304544.001]
  • [Cites] J Virol. 2004 Sep;78(18):9977-86 [15331731.001]
  • [Cites] Proc Natl Acad Sci U S A. 1967 Apr;57(4):933-40 [5231356.001]
  • [Cites] J Virol. 1999 Apr;73(4):2658-66 [10074111.001]
  • [Cites] J Virol. 1999 Jul;73(7):5957-69 [10364348.001]
  • [Cites] J Virol. 2004 Dec;78(24):13600-12 [15564471.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1374-8 [15531891.001]
  • [Cites] Curr Top Microbiol Immunol. 2005;287:57-94 [15609509.001]
  • [Cites] J Virol. 2005 Jan;79(2):884-95 [15613317.001]
  • [Cites] J Infect Dis. 2005 Feb 15;191(4):503-6 [15655772.001]
  • [Cites] J Med Virol. 2005 Mar;75(3):463-5 [15648061.001]
  • [Cites] J Med Virol. 2005 Mar;75(3):455-62 [15648064.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5 [15695582.001]
  • [Cites] J Virol. 2005 Apr;79(7):4550-1 [15767458.001]
  • [Cites] Clin Infect Dis. 2005 Jun 15;40(12):1721-9 [15909257.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93 [15897467.001]
  • [Cites] Pediatr Infect Dis J. 2005 Jul;24(7):645-6 [15999010.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):599-609 [16064136.001]
  • [Cites] Emerg Infect Dis. 2005 Aug;11(8):1225-9 [16102311.001]
  • [Cites] Mol Cell. 2005 Aug 19;19(4):547-57 [16109378.001]
  • [Cites] PLoS Med. 2005 Aug;2(8):e240 [16104827.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4567-73 [16145108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5 [16169905.001]
  • [Cites] PLoS Biol. 2005 Oct;3(10):e324 [16128623.001]
  • [Cites] Essays Biochem. 2005;41:139-56 [16250903.001]
  • [Cites] J Med Chem. 2005 Nov 3;48(22):6767-71 [16250632.001]
  • [Cites] Science. 2005 Oct 28;310(5748):676-9 [16195424.001]
  • [Cites] Structure. 2005 Nov;13(11):1665-75 [16271890.001]
  • [Cites] J Gen Virol. 1967 Apr;1(2):175-8 [4293939.001]
  • [Cites] Virology. 1992 Jul;189(1):274-84 [1318604.001]
  • [Cites] Virology. 1995 Jun 1;209(2):420-7 [7778277.001]
  • [Cites] Virology. 1995 Jun 1;209(2):489-97 [7539970.001]
  • [Cites] J Virol. 1997 Feb;71(2):900-9 [8995606.001]
  • [Cites] J Virol. 2000 Feb;74(4):1674-85 [10644337.001]
  • [Cites] J Virol. 2000 Sep;74(17):7911-21 [10933699.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):33220-32 [11431476.001]
  • [Cites] Virology. 1995 Apr 1;208(1):1-8 [11831690.001]
  • [Cites] J Virol. 2002 Apr;76(8):3697-708 [11907209.001]
  • [Cites] J Virol. 2002 Jun;76(12):6323-31 [12021365.001]
  • [Cites] Chem Biol. 2002 Oct;9(10):1149-59 [12401499.001]
  • [Cites] Lancet. 2003 Apr 19;361(9366):1319-25 [12711465.001]
  • [Cites] N Engl J Med. 2003 May 15;348(20):1967-76 [12690091.001]
  • [Cites] N Engl J Med. 2003 May 15;348(20):1953-66 [12690092.001]
  • [Cites] J Virol. 2003 Jul;77(13):7376-82 [12805436.001]
  • [Cites] J Gen Virol. 2003 Sep;84(Pt 9):2305-15 [12917450.001]
  • [Cites] J Virol. 2003 Oct;77(19):10515-27 [12970436.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:141-72 [14570567.001]
  • [Cites] J Biol Chem. 2004 Mar 12;279(11):10136-41 [14699140.001]
  • [Cites] Emerg Infect Dis. 2004 Feb;10(2):320-6 [15030705.001]
  • [Cites] Nat Med. 2004 Apr;10(4):368-73 [15034574.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6212-6 [15073334.001]
  • [Cites] Pediatr Infect Dis J. 2005 Nov;24(11):1015-7 [16282944.001]
  • [Cites] J Virol. 2005 Dec;79(24):15189-98 [16306590.001]
  • [Cites] J Virol. 2005 Dec;79(24):15199-208 [16306591.001]
  • [Cites] J Virol. 2005 Dec;79(24):15582-5 [16306630.001]
  • [Cites] Virol J. 2004;1:7 [15548333.001]
  • [Cites] Cell. 2005 Dec 2;123(5):773-86 [16325574.001]
  • [Cites] Proteins. 2006 Mar 15;62(3):760-75 [16358325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5717-22 [16581910.001]
  • [Cites] J Virol. 2006 May;80(9):4211-9 [16611880.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jun;50(6):2000-8 [16723558.001]
  • [Cites] J Virol. 2006 Jun;80(12):5927-40 [16731931.001]
  • [Cites] J Virol. 2006 Jun;80(12):6003-12 [16731939.001]
  • [Cites] PLoS Pathog. 2005 Dec;1(4):e39 [16341254.001]
  • [Cites] Clin Infect Dis. 2006 Sep 1;43(5):585-92 [16886150.001]
  • [Cites] J Virol. 2006 Sep;80(17):8639-52 [16912312.001]
  • [Cites] J Virol. 2006 Dec;80(23):11610-20 [16971428.001]
  • (PMID = 17392370.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / P01 AI060915; United States / NIAID NIH HHS / AI / P01-AI060915; United States / PHS HHS / / R01-A1045798
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ubiquitin; 0 / Viral Envelope Proteins; EC 3.4.22.- / 3C-like proteinase, Coronavirus; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.2 / Papain
  • [Other-IDs] NLM/ PMC1900296
  •  go-up   go-down


82. Mowery YM, Weinberg JB, Kennedy MN, Bond KM, Moore JO, Lanasa MC, Gockerman JP, Diehl LF, Pizzo SV, Cianciolo GJ, Friedman DR: LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells. Leukemia; 2010 Sep;24(9):1580-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.
  • B-cell chronic lymphocytic leukemia (CLL) is characterized by slow accumulation of malignant cells, which are supported in the microenvironment by cell-cell interactions and soluble cytokines such as tumor necrosis factor (TNF).
  • We evaluated the effect of the small molecule TNF inhibitor LMP-420 on primary CLL cells.
  • CLL cells from patients with poor prognostic indicators showed LMP-420 sensitivity equal to that for cells from patients with favorable characteristics.
  • In addition, LMP-420 potentiated the cytotoxic effect of fludarabine and inhibited in vitro proliferation of stimulated CLL cells.
  • Gene expression profiling indicated that the mechanism of action of LMP-420 may involve suppression of nuclear factor-kappaB and immune response pathways in CLL cells.
  • LMP-420 had minimal effects on normal peripheral blood mononuclear cell, B- and T-cell function, and hematopoietic colony formation.
  • Our data suggest that LMP-420 may be a useful treatment for CLL with negligible hematologic toxicities.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Boron Compounds / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Purines / pharmacology. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Synergism. Female. Flow Cytometry. Gene Expression Profiling. Humans. Male. Prognosis. Vidarabine / analogs & derivatives. Vidarabine / pharmacology

  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20613784.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2-amino-6-chloro-9-((5-dihydroxyboryl)pentyl)purine; 0 / Antineoplastic Agents; 0 / Boron Compounds; 0 / Purines; 0 / Tumor Necrosis Factor-alpha; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


83. Rezvany MR, Kazemi A, Hajifathali A, Kaviani S, Mellstedt H: Analysis of HLA-G gene expression in B-lymphocytes from chronic lymphocytic leukemia patients. Iran Biomed J; 2007 Apr;11(2):125-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of HLA-G gene expression in B-lymphocytes from chronic lymphocytic leukemia patients.
  • BACKGROUND: The human leukocyte antigen G (HLA-G) molecule exhibits limited tissue distribution, low polymorphism and alternative splicings that generate seven HLA-G isoforms.
  • This study it is an effort to clarify the presence of HLA-G in B-cell chronic lymphocytic leukemia (B-CLL) patients.
  • METHODS: HLA-G mRNA expression was studied in a pilot study in circulating B-CLL and also healthy controls by reverse transcription (RT)-PCR using a set of pan-HLA-G primers.
  • RESULTS: RT-PCR was performed on B-cells from 74 B-CLL patients and 12 healthy controls.
  • The data showed HLA-G gene expression in 20% of the B-CLL patients.
  • CONCLUSION: These data suggest that HLA-G is expressed at the gene level in B cells from B-CLL patients but not in B cells from healthy controls.
  • Further study is required to clarify the role of HLA-G as a regulatory factor that could affect immune response in B-CLL patients.
  • [MeSH-major] B-Lymphocytes / immunology. Gene Expression Regulation / immunology. HLA Antigens / genetics. Histocompatibility Antigens Class I / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / immunology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18051955.001).
  • [ISSN] 1028-852X
  • [Journal-full-title] Iranian biomedical journal
  • [ISO-abbreviation] Iran. Biomed. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / DNA Primers; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


84. Lu CM, Murata-Collins JL, Wang E, Siddiqi I, Lawrence H: Concurrent acute myeloid leukemia with inv(16)(p13.1q22) and chronic lymphocytic leukemia: molecular evidence of two separate diseases. Am J Hematol; 2006 Dec;81(12):963-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent acute myeloid leukemia with inv(16)(p13.1q22) and chronic lymphocytic leukemia: molecular evidence of two separate diseases.
  • Acute myeloid leukemia (AML) occurring concurrently with or after untreated chronic lymphocytic leukemia (CLL) is rare.
  • We report a case of a 59-year-old man who was evaluated for anemia, thrombocytopenia, and leukocytosis with circulating blasts.
  • On the basis of the morphology and immunophenotyping results, a preliminary diagnosis of chronic myelomonocytic leukemia with concurrent CLL was considered.
  • Subsequently, cytogenetic analysis of the leukemic blood specimen revealed inv(16)(p13.1q22) with secondary trisomy 22 in a sideline clone.
  • Fluorescence in situ hybridization confirmed the CBFbeta rearrangement associated with inv(16) in myeloblasts and myelomonocytic cells, but not in CLL cells.
  • Therefore, a final diagnosis of AML with inv(16) with concurrent CLL was made.
  • After standard chemotherapy for AML, the patient achieved complete remission for both his AML and CLL.
  • The unique aspects of this case include concomitant AML and CLL, which do not share clonality, complex cytogenetic abnormalities with trisomy 22 as a secondary abnormality associated with inv(16), and achievement of remission for both AML and CLL by AML chemotherapy regimen.
  • This case also represents one of the rare instances where a diagnosis of AML can be established even when the blast percentage in the marrow and blood is less than 20%.
  • [MeSH-major] Chromosome Inversion / genetics. Chromosomes, Human, Pair 16 / genetics. Chromosomes, Human, Pair 22 / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Myeloid, Acute / genetics. Neoplasms, Second Primary / genetics. Trisomy / genetics
  • [MeSH-minor] Blast Crisis / diagnosis. Blast Crisis / drug therapy. Blast Crisis / genetics. Blast Crisis / pathology. Bone Marrow / pathology. Humans. In Situ Hybridization, Fluorescence / methods. Male. Middle Aged. Remission Induction


85. Caraway NP, Thomas E, Khanna A, Payne L, Zhang HZ, Lin E, Keating MJ, Katz RL: Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival. Cancer; 2008 Oct 25;114(5):315-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival.
  • BACKGROUND: Fine-needle aspiration (FNA) of lymph nodes is commonly used to assess disease progression in patients with small lymphocytic lymphoma (SLL).
  • Although cytologic features are helpful for diagnosing typical SLL and transformed large-cell lymphoma (tLCL), SLL in accelerated phase (SLLacc) is more difficult to diagnose.
  • Additional tests are needed to identify those patients who are transforming to a higher-grade lymphoma.
  • This study evaluated the use of a multicolor fluorescence in situ hybridization (FISH) probe panel specifically designed for chronic lymphocytic leukemia (CLL)/SLL and assessed the association between FISH findings and cytologic diagnosis, proliferation index, and risk of death.
  • METHODS: FNA specimens from 50 patients (32 men and 18 women; mean age, 57 years [range, 36-77 years]) with histologically confirmed CLL and/or SLL were evaluated in this study for chromosomal abnormalities of 11q22 (ATM), 12, 13q14.3, 13q34.3 (LAMP1), and 17p13.1 (p53) by using a multiprobe FISH kit.
  • CONCLUSIONS: FISH can be performed on FNA specimens from patients with a history of SLL/CLL.
  • [MeSH-major] Biopsy, Fine-Needle. Chromosome Aberrations. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / mortality

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18683215.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Storey R, Gatt M, Bradford I: Mucosa associated lymphoid tissue lymphoma presenting within a solitary anti-mesenteric dilated segment of ileum: a case report. J Med Case Rep; 2009;3:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa associated lymphoid tissue lymphoma presenting within a solitary anti-mesenteric dilated segment of ileum: a case report.
  • INTRODUCTION: Mucosa associated lymphoid tissue (MALT) lymphoma is the third most common non-Hodgkin's lymphoma subtype.
  • Clinical presentation is often insidious as a low-grade lesion and disease tends to remain localised for a long period of time.
  • Histology of this segment demonstrated MALT lymphoma of the small bowel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2008;43(4):497-505 [18365916.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):529-33 [15729078.001]
  • [Cites] Leuk Lymphoma. 1997 Aug;26(5-6):527-37 [9389360.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2486-92 [10561313.001]
  • [Cites] Arch Surg. 1994 Jun;129(6):659-61 [8204043.001]
  • [Cites] Cancer. 1983 Jan 1;51(1):80-91 [6336974.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • (PMID = 19126231.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2627909
  •  go-up   go-down


87. Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H, German Chronic Lymphocytic Leukemia Study Group: Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol; 2009 Aug 20;27(24):3994-4001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
  • PURPOSE: The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL).
  • The median progression-free survival was 7.7 months, and the median overall survival (OS) was 19.1 months.
  • In multivariate analysis of clinical and biologic variables, age, performance status, beta2-MG, and TK were independent prognostic factors for OS.
  • CONCLUSION: Subcutaneous alemtuzumab appears as effective and safe as intravenous alemtuzumab in fludarabine-refractory CLL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597025.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


88. Giannopoulos K, Schmitt M, Własiuk P, Chen J, Bojarska-Junak A, Kowal M, Roliñski J, Dmoszyñska A: The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia; 2008 Jan;22(1):222-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. T-Lymphocytes, Regulatory / immunology. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / metabolism. Female. Forkhead Transcription Factors / metabolism. Humans. Interleukin-2 Receptor alpha Subunit / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657216.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Immunosuppressive Agents; 0 / Interleukin-2 Receptor alpha Subunit; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


89. Morrison VA: Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol; 2010 Mar;23(1):145-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches.
  • Infectious complications continue to be a major cause of morbidity and mortality in patients with chronic lymphocytic leukaemia (CLL).
  • This review focuses on the pathogenesis and risk factors for infections in patients with CLL, the spectrum of infectious complications and preventive approaches to infection in these patients, using antimicrobial and immunoglobulin prophylaxis and vaccination strategies.
  • [MeSH-major] Infection / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / complications

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ltd.
  • (PMID = 20620978.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 70
  •  go-up   go-down


90. Goldin LR, Lanasa MC, Slager SL, Cerhan JR, Vachon CM, Strom SS, Camp NJ, Spector LG, Leis JF, Morrison VA, Glenn M, Rabe KG, Achenbach SJ, Algood SD, Abbasi F, Fontaine L, Yau M, Rassenti LZ, Kay NE, Call TG, Hanson CA, Weinberg JB, Marti GE, Caporaso NE: Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol; 2010 Oct;151(2):152-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families.
  • Monoclonal B-cell lymphocytosis (MBL) is an asymptomatic haematological condition characterized by low absolute levels of B-cell clones with a surface immunophenotype similar to that of chronic lymphocytic leukaemia (CLL).
  • It has been reported to be higher among first-degree relatives from CLL families.
  • We report results of multi-parameter flow cytometry among 505 first-degree relatives with no personal history of lymphoproliferative disease from 140 families having at least two cases of CLL.
  • MBL clustered in certain families but clustering was independent of the number of known CLL cases in a family.
  • As is the case with CLL, males had a significantly higher risk for MBL than did females (P = 0·04).
  • MBL patients had significantly higher mean absolute lymphocyte counts (2·4 × 10(9) /l) and B-cell counts (0·53 × 10(9) /l) than those with a normal B-cell immuno-phenotype.
  • Our findings show that MBL occurs at a very high rate in high risk CLL families.
  • Both the age and gender distribution of MBL are parallel to CLL, implying a shared inherited risk.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2010. This article is a US Government work and is in the public domain in the USA.
  • [Cites] Br J Haematol. 2009 Nov;147(3):339-46 [19709083.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):3959-63 [19620484.001]
  • [Cites] Leukemia. 2010 Mar;24(3):512-20 [20090778.001]
  • [Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2289-90 [12239136.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 [12599176.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2337-42 [14630808.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):325-32 [16042682.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1087-91 [17577771.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Sep;72(5):344-53 [17266153.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Mayo Clin Proc. 2008 Jul;83(7):776-85 [18613994.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):575-83 [18687638.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):493-7 [19347733.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4188-96 [19015397.001]
  • [Cites] Haematologica. 2009 May;94(5):647-53 [19286886.001]
  • [Cites] Blood. 2009 Jul 2;114(1):26-32 [19029437.001]
  • [Cites] Blood. 2009 Jul 2;114(1):33-7 [19420353.001]
  • [Cites] Leukemia. 2010 Jan;24(1):133-40 [19946263.001]
  • (PMID = 20738309.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA118444; United States / NCI NIH HHS / PC / N01-PC-35141; United States / NCI NIH HHS / CA / N01PC35141; United States / NIAID NIH HHS / AI / P30 AI051445; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R43 CA137941; United States / NCI NIH HHS / CA / CA137941; United States / NIAID NIH HHS / AI / AI-51445; United States / NCI NIH HHS / CA / CA116237; United States / NCI NIH HHS / CA / U01 CA118444; United States / NCI NIH HHS / CA / R01 CA116237
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS230867; NLM/ PMC2966536
  •  go-up   go-down


91. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, Wiktor-Jedrzejczak W, Niederwieser D, Hallek M, Montserrat E, Chronic Leukemia Working Party of the EBMT: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia; 2007 Jan;21(1):12-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.
  • The aim of this project was to identify situations where allogeneic stem cell transplantation (allo-SCT) might be considered as a preferred treatment option for patients with B-cell chronic lymphocytic leukemia (CLL).
  • Key elements of the consensus are (1) allo-SCT is a procedure with evidence-based efficacy in poor-risk CLL;.
  • (2) although definition of 'poor-risk CLL' requires further investigation, allo-SCT is a reasonable treatment option for younger patients with (i) non-response or early relapse (within 12 months) after purine analogues, (ii) relapse within 24 months after having achieved a response with purine-analogue-based combination therapy or autologous transplantation, and (iii) patients with p53 abnormalities requiring treatment; and (3) optimum transplant strategies may vary according to distinct clinical situations and should be defined in prospective trials.
  • This is the first attempt to define standard indications for allo-SCT in CLL.
  • Nevertheless, whenever possible, allo-SCT should be performed within disease-specific prospective clinical protocols in order to continuously refine transplant indications according to new developments in risk assessment and treatment of CLL.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17109028.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Number-of-references] 43
  •  go-up   go-down


92. Hamblin TJ: Chronic lymphocytic leukaemia: clinical translations of biological features. Curr Top Microbiol Immunol; 2005;294:165-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukaemia: clinical translations of biological features.
  • The chronic lymphatic leukaemia (CLL) world was surprised to find that the disease split so neatly down the middle into those patients with unmutated immunoglobulin genes who were mainly men, had aggressive disease and were destined to die from their disease, on average at about 8 years from diagnosis, and those with mutated immunoglobulin genes who were equally distributed between the sexes, had indolent disease and usually died of something else a quarter of a century later.
  • This discovery gave fresh impetus to the investigation into the biology of CLL.
  • We now know more about, though we are still not certain of, the cell of origin of the disease and how it functions and fails to function.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • [MeSH-minor] B-Lymphocytes / immunology. Biomarkers, Tumor. Female. Genes, Immunoglobulin. Germinal Center / immunology. Humans. Immunologic Memory. Male. Mutation. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323432.001).
  • [ISSN] 0070-217X
  • [Journal-full-title] Current topics in microbiology and immunology
  • [ISO-abbreviation] Curr. Top. Microbiol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 77
  •  go-up   go-down


93. Masago M, Takaai M, Sakata J, Horie A, Ito T, Ishida K, Taguchi M, Hashimoto Y: Membrane transport mechanisms of quinidine and procainamide in renal LLC-PK1 and intestinal LS180 cells. Biol Pharm Bull; 2010;33(8):1407-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane transport mechanisms of quinidine and procainamide in renal LLC-PK1 and intestinal LS180 cells.
  • The aim of the present study was to compare the membrane transport mechanisms of procainamide with those of quinidine using renal epithelial LLC-PK(1) and intestinal epithelial LS180 cells.
  • In LLC-PK(1) cells, the transcellular transport of 10 microM quinidine in the basolateral-to-apical direction was similar to that in the opposite direction, and 1 mM tetraethylammonium (TEA) did not affect the transcellular transport of the drug.
  • On the other hand, the transcellular transport of 10 microM TEA and procainamide in LLC-PK(1) cells was directional from the basolateral side to the apical side.
  • [MeSH-major] Anti-Arrhythmia Agents / pharmacokinetics. Cell Membrane / metabolism. Intestines / metabolism. Kidney / metabolism. Procainamide / pharmacokinetics. Quinidine / pharmacokinetics
  • [MeSH-minor] Animals. Biological Transport, Active. Caco-2 Cells. Cation Transport Proteins / metabolism. Drug Interactions. Epithelial Cells / metabolism. Humans. Hydrogen-Ion Concentration. LLC-PK1 Cells. Swine. Temperature. Tetraethylammonium / pharmacology

  • Hazardous Substances Data Bank. PROCAINAMIDE .
  • Hazardous Substances Data Bank. QUINIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686239.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Cation Transport Proteins; 66-40-0 / Tetraethylammonium; ITX08688JL / Quinidine; L39WTC366D / Procainamide
  •  go-up   go-down


94. Cerezo M, Bandelt HJ, Martín-Guerrero I, Ardanaz M, Vega A, Carracedo A, García-Orad A, Salas A: High mitochondrial DNA stability in B-cell chronic lymphocytic leukemia. PLoS One; 2009;4(11):e7902
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High mitochondrial DNA stability in B-cell chronic lymphocytic leukemia.
  • BACKGROUND: Chronic Lymphocytic Leukemia (CLL) leads to progressive accumulation of lymphocytes in the blood, bone marrow, and lymphatic tissues.
  • Previous findings have suggested that the mtDNA could play an important role in CLL.
  • METHODOLOGY/PRINCIPAL FINDINGS: The mitochondrial DNA (mtDNA) control-region was analyzed in lymphocyte cell DNA extracts and compared with their granulocyte counterpart extract of 146 patients suffering from B-Cell CLL; B-CLL (all recruited from the Basque country).
  • Only twenty instabilities were finally confirmed, most of them affecting the homopolymeric stretch located in the second hypervariable segment (HVS-II) around position 310, which is well known to constitute an extreme mutational hotspot of length polymorphism, as these mutations are frequently observed in the general human population.
  • A critical revision of the findings in previous studies indicates a lack of proper methodological standards, which eventually led to an overinterpretation of the role of the mtDNA in CLL tumorigenesis.
  • CONCLUSIONS/SIGNIFICANCE: Our results suggest that mtDNA instability is not the primary causal factor in B-CLL.
  • [MeSH-major] DNA, Mitochondrial / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • [MeSH-minor] Base Sequence. DNA Primers / genetics. Databases, Genetic. Granulocytes / cytology. Haplotypes. Humans. Lymphocytes / cytology. Models, Statistical. Molecular Sequence Data. Mutation. Phylogeny. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2009;9:113 [19371404.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):122-30 [15958208.001]
  • [Cites] Forensic Sci Int. 2000 May 8;110(1):47-59 [10802200.001]
  • [Cites] Am J Hum Genet. 2000 Nov;67(5):1251-76 [11032788.001]
  • [Cites] Leukemia. 2001 Mar;15(3):445-51 [11237069.001]
  • [Cites] Int J Legal Med. 2001;114(3):186-90 [11296893.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1317-25 [11516091.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 30;335(3):891-9 [16102729.001]
  • [Cites] Electrophoresis. 2005 Sep;26(18):3414-29 [16167362.001]
  • [Cites] J Med Genet. 2005 Dec;42(12):957-60 [15923271.001]
  • [Cites] Leukemia. 2006 Feb;20(2):362-3 [16357835.001]
  • [Cites] Genetics. 2006 Jan;172(1):373-87 [16172508.001]
  • [Cites] PLoS Med. 2005 Nov;2(11):e296 [16187796.001]
  • [Cites] Hum Genet. 2006 Jun;119(5):505-15 [16528519.001]
  • [Cites] Blood. 2007 Jan 15;109(2):756-62 [16946307.001]
  • [Cites] Mol Biol Evol. 2007 Feb;24(2):436-48 [17099056.001]
  • [Cites] Mol Biol Evol. 2007 Mar;24(3):868-74 [17218641.001]
  • [Cites] Forensic Sci Int. 2007 May 3;168(1):1-13 [16814504.001]
  • [Cites] PLoS One. 2008;3(4):e2062 [18446216.001]
  • [Cites] J Med Genet. 2008 Dec;45(12):769-72 [18611982.001]
  • [Cites] PLoS One. 2009;4(4):e5112 [19340307.001]
  • [Cites] Am J Hum Genet. 2002 May;70(5):1152-71 [11938495.001]
  • [Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]
  • [Cites] Am J Hum Genet. 2002 Nov;71(5):1150-60 [12384858.001]
  • [Cites] Am J Phys Anthropol. 2003 Apr;120(4):391-404 [12627534.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3118-25 [12446454.001]
  • [Cites] Electrophoresis. 2003 Apr;24(7-8):1159-65 [12707907.001]
  • [Cites] Int J Legal Med. 2003 Jun;117(3):180-4 [12799738.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1437-47 [12886229.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2487-91 [14523470.001]
  • [Cites] Leukemia. 2004 Jan;18(1):18-22 [14614516.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1314-20 [14647457.001]
  • [Cites] Forensic Sci Int. 2004 Feb 10;140(1):1-11 [15013160.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1966-71 [15026331.001]
  • [Cites] Forensic Sci Int. 2004 Mar 10;140(2-3):251-7 [15036446.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1313-6 [15129223.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1402-4 [15353782.001]
  • [Cites] Am J Hum Genet. 2004 Nov;75(5):910-8 [15382008.001]
  • [Cites] Ann Hum Genet. 1991 Jan;55(Pt 1):51-67 [2042936.001]
  • [Cites] Int J Legal Med. 1993;105(5):251-6 [8471542.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1052-7 [7675049.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Int J Cancer. 1998 May 18;76(4):495-8 [9590124.001]
  • [Cites] Ann Intern Med. 1998 Oct 1;129(7):559-66 [9758577.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1612-7 [9766507.001]
  • [Cites] Eur J Hum Genet. 1998 Jul-Aug;6(4):365-75 [9781045.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):147 [10508508.001]
  • [Cites] Forensic Sci Int. 2005 Mar 10;148(2-3):191-8 [15639614.001]
  • [Cites] Int J Legal Med. 2004 Oct;118(5):267-73 [15257464.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Am J Hum Genet. 2005 May;76(5):883-6 [15791543.001]
  • [Cites] Electrophoresis. 2000 Feb;21(3):548-53 [10726758.001]
  • (PMID = 19924307.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ PMC2775629
  •  go-up   go-down


95. Wang J, Zhang B, Guo Y, Li G, Xie Q, Zhu B, Gao J, Chen Z: Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. Pharmacology; 2008;82(2):148-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously reported that dihydroartemisinin is found to have a potent ability in influencing lymphatic endothelial cell migration and tube formation.
  • In this study, we investigated the effect of artemisinin on tumor growth, lymphangiogenesis, metastasis and survival in mouse Lewis lung carcinoma (LLC) models.
  • Furthermore, IL-1beta-induced p38 mitogen-activated protein kinase (MAPK) activation and upregulation of VEGF-C mRNA and protein in LLC cells was also suppressed by artemisinin or by the p38 MAPK inhibitor SB-203580, suggesting that p38 MAPK could serve as a mediator of proinflammatory cytokine-induced VEGF-C expression.
  • [MeSH-minor] Administration, Oral. Animals. Female. Gene Expression Regulation, Neoplastic / drug effects. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Lymphangiogenesis / drug effects. Lymphatic Metastasis / prevention & control. Mice. Mice, Inbred C57BL. Neoplasm Metastasis / prevention & control. Survival Rate. p38 Mitogen-Activated Protein Kinases / drug effects. p38 Mitogen-Activated Protein Kinases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18667841.001).
  • [ISSN] 1423-0313
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Artemisinins; 0 / Vascular Endothelial Growth Factor C; 9RMU91N5K2 / artemisinine; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


96. Sleep 2009. Abstracts of the 23rd Annual Meeting of the Associated Professional Sleep Societies, LLC. June 6-11, 2009. Seattle, Washington, USA. Sleep; 2009;32 Suppl:A1-427
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sleep 2009. Abstracts of the 23rd Annual Meeting of the Associated Professional Sleep Societies, LLC. June 6-11, 2009. Seattle, Washington, USA.

  • MedlinePlus Health Information. consumer health - Sleep Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760817.001).
  • [ISSN] 0161-8105
  • [Journal-full-title] Sleep
  • [ISO-abbreviation] Sleep
  • [Language] eng
  • [Publication-type] Congresses; Overall
  • [Publication-country] United States
  •  go-up   go-down


97. Szmigielska-Kapłon A, Jesionek-Kupnicka D, Góra-Tybor J, Błonski JZ, Lech-Marańda E, Kordek R, Kasznicki M, Robak T: Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia. Leuk Lymphoma; 2007 May;48(5):1042-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia.
  • [MeSH-major] Bone Marrow Cells / drug effects. Cladribine / administration & dosage. Cladribine / therapeutic use. Cyclophosphamide / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Mitoxantrone / administration & dosage. Neovascularization, Pathologic

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487753.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


98. Payne PR, Borlawsky TB, Stephens W, Barrett MC, Nguyen-Pham T, Greaves AW: The TRITON Project: Design and Implementation of an Integrative Translational Research Information Management Platform. AMIA Annu Symp Proc; 2010 Nov 13;2010:617-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Chronic Lymphocytic Leukemia (CLL) Research Consortium (CRC), a s a prototypical instance of such a consortia, uses numerous loosely coupled web applications to address its informatics needs.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Med Inform Assoc. 2008 Mar-Apr;15(2):138-49 [18096909.001]
  • [Cites] AMIA Annu Symp Proc. 2007;:433-7 [18693873.001]
  • [Cites] AMIA Annu Symp Proc. 2008;:1087 [18998940.001]
  • [Cites] AMIA Annu Symp Proc. 2008;:566-70 [18998958.001]
  • [Cites] Mol Cell Biochem. 2009 May;325(1-2):41-51 [19139973.001]
  • [Cites] J Am Med Inform Assoc. 2009 May-Jun;16(3):305-15 [19261933.001]
  • [Cites] Bioinformatics. 2006 Aug 1;22(15):1910-6 [16766552.001]
  • (PMID = 21347052.001).
  • [ISSN] 1942-597X
  • [Journal-full-title] AMIA ... Annual Symposium proceedings. AMIA Symposium
  • [ISO-abbreviation] AMIA Annu Symp Proc
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / R01 CA134232
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 30IQX730WE / Polyethylene Glycols
  • [Other-IDs] NLM/ PMC3041280
  •  go-up   go-down


99. Carulli G, Cannizzo E, Zucca A, Buda G, Orciuolo E, Marini A, Petrini M: CD45 expression in low-grade B-cell non-Hodgkin's lymphomas. Leuk Res; 2008 Feb;32(2):263-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD45 expression in low-grade B-cell non-Hodgkin's lymphomas.
  • Few data are available about CD45 expression in the various types of low-grade B-cell non-Hodgkin's lymphomas (NHL).
  • Low levels of CD45 have been reported in pathologic lymphocytes from typical chronic lymphocytic leukemia (CLL) and higher levels of this antigen have been observed in some cases of atypical CLL and in some cases of other types of NHL.
  • One hundred and seven bone marrow samples of NHL with bone marrow infiltration were investigated: 45 typical CLL, 15 atypical CLL, 9 mantle cell lymphomas (MCL), 1 MCL with CD23 expression, 18 marginal zone lymphomas (MZL), 6 lymphoplasmacytic lymphomas (LPL), 6 follicular lymphomas (FL), and 7 hairy cell leukemias (HCL).
  • CD45 expression was evaluated by flow cytometry: pathologic lymphocytes were identified on the basis of specific immunophenotypic profile, CD19/K or CD19/lambda co-expression.
  • CD45 expression was measured also on autologous T-lymphocytes and a "CD45 index" was calculated as the ratio MFI of pathologic B-lymphocytes/MFI of T-lymphocytes, to normalize the results obtained.
  • We found four CD45 expression patterns: very low in typical CLL; relatively low in MCL; intermediate intensity in MZL, LPL, and FL; very high expression in HCL.
  • Among the atypical cases, very high CD45 expression was found in one case of CD23-negative CLL, in CD23-positive MCL, and CLL with atypical morphology.
  • The results indicate different levels of maturation in low-grade NHL and may help to characterize such neoplasias.
  • [MeSH-major] Antigens, CD45 / biosynthesis. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Flow Cytometry. Humans. Immunophenotyping. Leukemia, Hairy Cell / metabolism. Leukemia, Hairy Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Lymphoma, Mantle-Cell / metabolism. Lymphoma, Mantle-Cell / pathology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692374.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


100. Giannopoulos K, Schmitt M: Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma; 2006 Oct;47(10):2028-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia.
  • T-cell based immunotherapies might be a novel option for the treatment of B-cell